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Abstract Objective: To provide
an update to the original Surviving
Sepsis Campaign clinical manage-
ment guidelines, “Surviving Sepsis
Campaign guidelines for management
of severe sepsis and septic shock,”
published in 2004. Design: Modified
Delphi method with a consensus
conference of 55 international ex-
perts, several subsequent meetings
of subgroups and key individuals,
teleconferences, and electronic-based
discussion among subgroups and
among the entire committee. This
process was conducted independently
of any industry funding. Methods:
We used the GRADE system to
guide assessment of quality of evi-
dence from high (A) to very low (D)
and to determine the strength of
recommendations. A strong rec-
ommendation [1] indicates that an
intervention’s desirable effects clearly
outweigh its undesirable effects (risk,
burden, cost), or clearly do not. Weak
recommendations [2] indicate that
the tradeoff between desirable and
undesirable effects is less clear. The
grade of strong or weak is considered
of greater clinical importance than
a difference in letter level of quality
of evidence. In areas without complete
agreement, a formal process of re-
solution was developed and applied.
Recommendations are grouped into
those directly targeting severe sepsis,
recommendations targeting general
care of the critically ill patient that
are considered high priority in severe
sepsis, and pediatric considerations.
Results: Key recommendations,
listed by category, include: early
goal-directed resuscitation of the
septic patient during the first 6 hrs
after recognition (1C); blood cultures
prior to antibiotic therapy (1C); imag-
ing studies performed promptly to
confirm potential source of infection
(1C); administration of broad-
spectrum antibiotic therapy within
1 hr of diagnosis of septic shock (1B)
and severe sepsis without septic shock
(1D); reassessment of antibiotic ther-
apy with microbiology and clinical
data to narrow coverage, when ap-
propriate (1C); a usual 7–10 days of
antibiotic therapy guided by clinical
response (1D); source control with
attention to the balance of risks and
benefits of the chosen method (1C);
administration of either crystalloid or
colloid fluid resuscitation (1B); fluid
challenge to restore mean circulating
filling pressure (1C); reduction in rate
of fluid administration with rising
filing pressures and no improvement
in tissue perfusion (1D); vasopressor
preference for norepinephrine or
dopamine to maintain an initial target
of mean arterial pressure ≥ 65 mm Hg
(1C); dobutamine inotropic therapy
when cardiac output remains low
despite fluid resuscitation and com-
bined inotropic/vasopressor therapy
(1C); stress-dose steroid therapy
given only in septic shock after blood
pressure is identified to be poorly
responsive to fluid and vasopressor
therapy (2C); recombinant activated
protein C in patients with severe
sepsis and clinical assessment of high
risk for death (2B except 2C for post-
operative patients). In the absence of
tissue hypoperfusion, coronary artery
disease, or acute hemorrhage, target
a hemoglobin of 7–9 g/dL (1B); a low
tidal volume (1B) and limitation of
inspiratory plateau pressure strategy
(1C) for acute lung injury (ALI)/
acute respiratory distress syndrome
(ARDS); application of at least
a minimal amount of positive end-
expiratory pressure in acute lung
injury (1C); head of bed elevation
in mechanically ventilated patients
unless contraindicated (1B); avoid-
ing routine use of pulmonary artery
catheters in ALI/ARDS (1A); to de-
crease days of mechanical ventilation
and ICU length of stay, a conserva-
tive fluid strategy for patients with
established ALI/ARDS who are not
in shock (1C); protocols for weaning
and sedation/analgesia (1B); using
either intermittent bolus sedation or
continuous infusion sedation with
daily interruptions or lightening (1B);
avoidance of neuromuscular blockers,
if at all possible (1B); institution
of glycemic control (1B) targeting
a blood glucose < 150 mg/dL after
initial stabilization ( 2C ); equivalency
of continuous veno-veno hemofiltra-
tion or intermittent hemodialysis
(2B); prophylaxis for deep vein
thrombosis (1A); use of stress ulcer
prophylaxis to prevent upper GI
bleeding using H2 blockers (1A) or
proton pump inhibitors (1B); and
consideration of limitation of support
where appropriate (1D). Recommen-
dations specific to pediatric severe
sepsis include: greater use of physical
examination therapeutic end points
(2C); dopamine as the first drug of
choice for hypotension (2C); steroids
only in children with suspected or
proven adrenal insufficiency (2C);
a recommendation against the use of
recombinant activated protein C in
children (1B). Conclusion: There
was strong agreement among a large
cohort of international experts regard-
ing many level 1 recommendations
for the best current care of patients
with severe sepsis. Evidenced-based
recommendations regarding the acute
management of sepsis and septic
shock are the first step toward im-
proved outcomes for this important
group of critically ill patients.
Keywords Sepsis · Severe sepsis ·
Septic shock · Sepsis syndrome ·
Infection · GRADE · Guidelines ·
Evidence-based medicine · Surviving
Sepsis Campaign · Sepsis bundles
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Introduction
Severe sepsis (acute organ dysfunction secondary to in-
fection) and septic shock (severe sepsis plus hypotension
not reversed with fluid resuscitation) are major healthcare
problems, affecting millions of individuals around the
world each year, killing one in four (and often more),
and increasing in incidence [1–5]. Similar to polytrauma,
acute myocardial infarction, or stroke, the speed and
appropriateness of therapy administered in the initial
hours after severe sepsis develops are likely to influence
outcome. In 2004, an international group of experts in the
diagnosis and management of infection and sepsis, repre-
senting 11 organizations, published the first internationally
accepted guidelines that the bedside clinician could use to
improve outcomes in severe sepsis and septic shock [6, 7].
These guidelines represented Phase II of the Surviving
Sepsis Campaign (SSC), an international effort to increase
awareness and improve outcomes in severe sepsis. Joined
by additional organizations, the group met again in 2006
and 2007 to update the guidelines document using a new
evidence-based methodology system for assessing quality
of evidence and strength of recommendations [8–11].
These recommendations are intended to provide guid-
ance for the clinician caring for a patient with severe sepsis
or septic shock. Recommendations from these guidelines
cannot replace the clinician’s decision-making capability
• Underlying methodology
A RCT
B Downgraded RCT or upgraded observational studies
C Well-done observational studies
D Case series or expert opinion
• Factors that may decrease the strength of evidence
1. Poor quality of planning and implementation of available RCTs suggesting high likelihood of bias
2. Inconsistency of results (including problems with subgroup analyses)
3. Indirectness of evidence (differing population, intervention, control, outcomes, comparison)
4. Imprecision of results
5. High likelihood of reporting bias
• Main factors that may increase the strength of evidence
1. Large magnitude of effect (direct evidence, relative risk (RR) > 2 with no plausible confounders)
2. Very large magnitude of effect with RR > 5 and no threats to validity (by two levels)
3. Dose response gradient
RCT, randomized controlled trial; RR, relative risk
Table 1 Determination
of the Quality of Evidence
Table 2 Factors Determining Strong vs. Weak Recommendation
What should be considered Recommended Process
Quality of evidence The lower the quality of evidence the less likely a strong recommendation
Relative importance of the outcomes If values and preferences vary widely, a strong recommendation becomes less likely
Baseline risks of outcomes The higher the risk, the greater the magnitude of benefit
Magnitude of relative risk including Larger relative risk reductions or larger increases in relative risk of harm make a strong
benefits, harms, and burden recommendation more or less likely respectively
Absolute magnitude of the effect The larger the absolute benefits and harms, the greater or
lesser likelihood respectively of a strong recommendation
Precision of the estimates of the effects The greater the precision the more likely is a strong recommendation
Costs The higher the cost of treatment, the less likely a strong recommendation
when he or she is provided with a patient’s unique set of
clinical variables. Most of these recommendations are ap-
propriate for the severe sepsis patient in both the intensive
care unit (ICU) and non-ICU settings. In fact the commit-
tee believes that, currently, the greatest outcome improve-
ment can be made through education and process change
for those caring for severe sepsis patients in the non-ICU
setting and across the spectrum of acute care. It should also
be noted that resource limitations in some institutions and
countries may prevent physicians from accomplishing par-
ticular recommendations.
Methods
Sepsis is defined as infection plus systemic manifestations
of infection (Table 1) [12]. Severe sepsis is defined as
sepsis plus sepsis-induced organ dysfunction or tissue
hypoperfusion. The threshold for this dysfunction has
varied somewhat from one severe sepsis research study to
another. An example of typical thresholds identification
of severe sepsis is shown in Table 2 [13]. Sepsis induced
hypotension is defined as a systolic blood pressure(SBP)
of < 90 mm Hg or mean arterial pressure < 70 mm Hg or
a SBP decrease > 40 mm Hg or < 2 SD below normal
for age in the absence of other causes of hypotension.
Septic shock is defined as sepsis induced hypotension
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persisting despite adequate fluid resuscitation. Sepsis
induced tissue hypoperfusion is defined as either septic
shock, an elevated lactate or oliguria.
The current clinical practice guidelines build on
the first and second editions from 2001 (see below)
and 2004 [6, 7, 14]. The 2001 publication incorporated
a MEDLINE search for clinical trials in the preceding
10 years, supplemented by a manual search of other rele-
vant journals [14]. The 2004 publication incorporated the
evidence available through the end of 2003. The current
publication is based on an updated search into 2007 (see
methods and rules below).
The 2001 guidelines were coordinated by the Inter-
national Sepsis Forum (ISF); the 2004 guidelines were
funded by unrestricted educational grants from industry
and administered through the Society of Critical Care
Medicine (SCCM), the European Society of Intensive
Care Medicine (ESICM), and ISF. Two of the SSC
administering organizations receive unrestricted industry
funding to support SSC activities (ESICM and SCCM), but
none of this funding was used to support the 2006–2007
committee meetings.
It is important to distinguish between the process of
guidelines revision and the Surviving Sepsis Campaign.
The Surviving Sepsis Campaign (SSC) is partially funded
by unrestricted educational industry grants, including
those from Edwards LifeSciences, Eli Lilly and Com-
pany, and Philips Medical Systems. SSC also received
funding from the Coalition for Critical Care Excellence
of the Society of Critical Care Medicine. The great
majority of industry funding has come from Eli Lilly and
Company.
Current industry funding for the Surviving Sepsis Cam-
paign is directed to the performance improvement initia-
tive. No industry funding was used in the guidelines revi-
sion process.
For both the 2004 and the 2006/2007 efforts there were
no members of the committee from industry, no industry
input into guidelines development, and no industry pres-
ence at any of the meetings. Industry awareness or com-
ment on the recommendations was not allowed. No mem-
ber of the guideline committee received any honoraria for
any role in the 2004 or 2006/2007 guidelines process. The
committee considered the issue of recusement of individ-
ual committee members during deliberation and decision
making in areas where committee members had either fi-
nancial or academic competing interests; however, consen-
sus as to threshold for exclusion could not be reached. Al-
ternatively, the committee agreed to ensure full disclosure
and transparency of all committee members’ potential con-
flicts at time of publication (see disclosures at the end of
this document).
The guidelines process included a modified Delphi
method, a consensus conference, several subsequent meet-
ings of subgroups and key individuals, teleconferences
and electronically based discussions among subgroups
and members of the entire committee and two follow-up
nominal group meetings in 2007.
Subgroups were formed, each charged with updating
recommendations in specific areas, including corti-
costeroids, blood products, activated protein C, renal
replacement therapy, antibiotics, source control, and
glucose control, etc. Each subgroup was responsible for
updating the evidence (into 2007, with major additional
elements of information incorporated into the evolving
manuscript throughout 2006 and 2007). A separate search
was performed for each clearly defined question. The
committee chair worked with subgroup heads to identify
pertinent search terms that always included, at a minimum,
sepsis, severe sepsis, septic shock and sepsis syndrome
crossed against the general topic area of the subgroup as
well as pertinent key words of the specific question posed.
All questions of the previous guidelines publications were
searched, as were pertinent new questions generated by
general topic related search or recent trials. Quality of
evidence was judged by pre-defined Grades of Recom-
mendation, Assessment, Development and Evaluation
(GRADE) criteria (see below). Significant education
of committee members on the GRADE approach was
performed via email prior to the first committee meeting
and at the first meeting. Rules were distributed concerning
assessing the body of evidence and GRADE experts were
available for questions throughout the process. Subgroups
agreed electronically on draft proposals that were pre-
sented to committee meetings for general discussion. In
January 2006, the entire group met during the 35th SCCM
Critical Care Congress in San Francisco, California, USA.
The results of that discussion were incorporated into the
next version of recommendations and again discussed
using electronic mail. Recommendations were finalized
during nominal group meetings (composed of a subset of
the committee members) at the 2007 SCCM (Orlando)
and 2007 International Symposium on Intensive Care and
Emergency Medicine (Brussels) meetings with recircu-
lation of deliberations and decisions to the entire group
for comment or approval. At the discretion of the chair
and following adequate discussion, competing proposals
for wording of recommendations or assigning strength of
evidence were resolved by formal voting. On occasions,
voting was performed to give the committee a sense of
distribution of opinions to facilitate additional discussion.
The manuscript was edited for style and form by the
writing committee with final approval by section leads for
their respective group assignment and then by the entire
committee.
The development of guidelines and grading of recom-
mendations for the 2004 guideline development process
were based on a system proposed by Sackett in 1989,
during one of the first American College of Chest Physi-
cians (ACCP) conferences on the use of antithrombotic
therapies [15]. The revised guidelines recommendations
are based on the Grades of Recommendation, Assessment,
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Development and Evaluation (GRADE) system – a struc-
tured system for rating quality of evidence and grading
strength of recommendation in clinical practice [8–11].
The SSC Steering Committee and individual authors
collaborated with GRADE representatives to apply the
GRADE system to the SSC guidelines revision process.
The members of GRADE group were directly involved,
either in person or via e-mail, in all discussions and
deliberations amongst the guidelines committee members
as to grading decisions. Subsequently, the SSC authors
used written material prepared by the GRADE group
and conferred with GRADE group members who were
available at the first committee meeting and subsequent
nominal group meetings. GRADE representatives were
also used as a resource throughout subgroup delibera-
tion.
The GRADE system is based on a sequential assess-
ment of the quality of evidence, followed by assessment
of the balance between benefits versus risks, burden, and
cost and, based on the above, development and grading of
a management recommendations [9–11]. Keeping the rat-
ing of quality of evidence and strength of recommendation
explicitly separate constitutes a crucial and defining fea-
ture of the GRADE approach. This system classifies qual-
ity of evidence as high (Grade A), moderate (Grade B), low
(Grade C), or very low (Grade D). Randomized trials be-
gin as high quality evidence, but may be downgraded due
to limitations in implementation, inconsistency or impreci-
sion of the results, indirectness of the evidence, and possi-
ble reporting bias (see Table 1). Examples of indirectness
of the evidence include: population studied, interventions
used, outcomes measured, and how these relate to the ques-
tion of interest. Observational (non-randomized) studies
begin as low-quality evidence, but the quality level may
be upgraded on the basis of large magnitude of effect. An
example of this is the quality of evidence for early admin-
istration of antibiotics.
The GRADE system classifies recommendations as
strong (Grade 1) or weak (Grade 2). The grade of strong
or weak is considered of greater clinical importance than
a difference in letter level of quality of evidence. The com-
mittee assessed whether the desirable effects of adherence
will outweigh the undesirable effects, and the strength
of a recommendation reflects the group’s degree of con-
fidence in that assessment. A strong recommendation in
favor of an intervention reflects that the desirable effects
of adherence to a recommendation (beneficial health out-
comes, less burden on staff and patients, and cost savings)
will clearly outweigh the undesirable effects (harms, more
burden and greater costs). A weak recommendation in
favor of an intervention indicates that the desirable effects
of adherence to a recommendation probably will outweigh
the undesirable effects, but the panel is not confident about
these tradeoffs – either because some of the evidence is
low-quality (and thus there remains uncertainty regarding
the benefits and risks) or the benefits and downsides are
closely balanced. While the degree of confidence is a con-
tinuum and there is a lack of a precise threshold between
a strong and a weak recommendation, the presence of
important concerns about one or more of the above factors
makes a weak recommendation more likely. A “strong”
recommendation is worded as “we recommend” and
a weak recommendation as “we suggest.”
The implications of calling a recommendation “strong”
are that most well-informed patients would accept that
intervention, and that most clinicians should use it in
most situations. There may be circumstances in which
a “strong” recommendation cannot or should not be
followed for an individual patient because of that patient’s
preferences or clinical characteristics which make the
recommendation less applicable. It should be noted that
being a “strong” recommendation does not automatically
imply standard of care. For example, the strong recom-
mendation for administering antibiotics within one hour
of the diagnosis of severe sepsis, although desirable,
is not currently standard of care as verified by current
practice (personal communication, Mitchell Levy from
first 8,000 patients entered internationally into the SSC
performance improvement data base). The implication of
a “weak” recommendation is that although a majority of
well-informed patients would accept it (but a substantial
proportion would not), clinicians should consider its use
according to particular circumstance.
Differences of opinion among committee members
about interpretation of evidence, wording of proposals,
or strength of recommendations were resolved using
a specifically developed set of rules. We will describe this
process in detail in a separate publication. In summary,
the main approach for converting diverse opinions into
a recommendation was: 1. to give a recommendation
a direction (for or against the given action). a majority
of votes were to be in favor of that direction, with no
more than 20% preferring the opposite direction (there
was a neutral vote allowed as well); 2. to call a given
recommendation “strong” rather than “weak” at least 70%
“strong” votes were required; 3. if fewer than 70% of votes
indicated “strong” preference, the recommendation was
assigned a “weak” category of strength. We used a combi-
nation of modified Delphi Process and Nominal (Expert)
Group techniques to ensure both depth and breadth of
review. The entire review group (together with their
parent organizations as required) participated in the larger,
iterative, modified Delphi process. The smaller working
group meetings which took place in person functioned as
the Nominal Groups. If a clear consensus could not be
obtained by polling within the Nominal Group meetings,
the larger group was specifically asked to use the polling
process. This was only required for corticosteroids and
glycemic control. The larger group had the opportunity to
review all outputs. In this way the entire review combined
intense focused discussion (Nominal Group) with broader
review and monitoring using the Delphi process.
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Note: Refer to Tables 3, 4, and 5 for condensed adult
recommentations.
I. Management of Severe Sepsis
A. Initial Resuscitation
1. We recommend the protocolized resuscitation of
a patient with sepsis-induced shock, defined as tissue
hypoperfusion (hypotension persisting after initial
fluid challenge or blood lactate concentration equal
to or greater than 4 mmol/L). This protocol should be
initiated as soon as hypoperfusion is recognized and
should not be delayed pending ICU admission. During
the first 6 hrs of resuscitation, the goals of initial
resuscitation of sepsis-induced hypoperfusion should
Table 3 Initial Resuscitation and Infection Issues
Initial resuscitation (first 6 hours)
Strength of recommendation and quality of evidence have been assessed using the GRADE criteria, presented in brackets after each guide-
line. For added clarity: • Indicates a strong recommendation or “we recommend”; ◦ indicates a weak recommendation or “we suggest”
• Begin resuscitation immediately in patients with hypotension or elevated serum lactate > 4mmol/l; do not delay pending ICU
admission. (1C)• Resuscitation goals: (1C)
– Central venous pressure (CVP) 8–12 mm Hg*
– Mean arterial pressure ≥ 65 mm Hg
– Urine output ≥ 0.5 mL.kg-1.hr-1
– Central venous (superior vena cava) oxygen saturation ≥ 70%, or mixed venous ≥ 65%
◦ If venous O2 saturation target not achieved: (2C)
– consider further fluid
– transfuse packed red blood cells if required to hematocrit of ≥ 30% and/or
– dobutamine infusion max 20 µg.kg−1.min−1∗ A higher target CVP of 12–15 mmHg is recommended in the presence of mechanical ventilation or pre-existing decreased
ventricular compliance.
Diagnosis
• Obtain appropriate cultures before starting antibiotics provided this does not significantly delay antimicrobial administration. (1C)
– Obtain two or more blood cultures (BCs)
– One or more BCs should be percutaneous
– One BC from each vascular access device in place > 48 h
– Culture other sites as clinically indicated
• Perform imaging studies promptly in order to confirm and sample any source of infection; if safe to do so. (1C)
Antibiotic therapy
• Begin intravenous antibiotics as early as possible, and always within the first hour of recognizing severe sepsis (1D)
and septic shock (1B).• Broad-spectrum: one or more agents active against likely bacterial/fungal pathogens and with good penetration
into presumed source.(1B)• Reassess antimicrobial regimen daily to optimise efficacy, prevent resistance, avoid toxicity & minimise costs. (1C)◦ Consider combination therapy in Pseudomonas infections. (2D)◦ Consider combination empiric therapy in neutropenic patients. (2D)◦ Combination therapy no more than 3–5 days and deescalation following susceptibilities. (2D)• Duration of therapy typically limited to 7–10 days; longer if response slow, undrainable foci of infection,
or immunologic deficiencies. (1D)• Stop antimicrobial therapy if cause is found to be non-infectious. (1D)
Source identification and control
• A specific anatomic site of infection should be established as rapidly as possible (1C) and within first 6 hrs of presentation (1D).• Formally evaluate patient for a focus of infection amenable to source control measures (eg: abscess drainage, tissue debridement). (1C)• Implement source control measures as soon as possible following successful initial resuscitation. (1C)
Exception: infected pancreatic necrosis, where surgical intervention best delayed. (2B)• Choose source control measure with maximum efficacy and minimal physiologic upset. (1D)• Remove intravascular access devices if potentially infected. (1C)
include all of the following as one part of a treatment
protocol:
Central venous pressure (CVP): 8–12 mm Hg
Mean arterial pressure (MAP) ≥ 65 mm Hg
Urine output ≥ 0.5 mL.kg–1.hr –1
Central venous (superior vena cava) or mixed
venous oxygen saturation ≥ 70% or ≥ 65%, re-
spectively (Grade 1C)
Rationale. Early goal-directed resuscitation has been
shown to improve survival for emergency department
patients presenting with septic shock in a randomized,
controlled, single-center study [16]. Resuscitation di-
rected toward the previously mentioned goals for the
initial 6-hr period of the resuscitation was able to reduce
28-day mortality rate. The consensus panel judged use
23
Table 4 Hemodynamic Support and Adjunctive Therapy
Fluid therapy
Strength of recommendation and quality of evidence have been assessed using the GRADE criteria, presented in brackets after each guide-
line. For added clarity: • Indicates a strong recommendation or “we recommend”; ◦ indicates a weak recommendation or “we suggest”
• Fluid-resuscitate using crystalloids or colloids. (1B)• Target a CVP of ≥ 8 mm Hg (≥ 12 mm Hg if mechanically ventilated). (1C)• Use a fluid challenge technique while associated with a haemodynamic improvement. (1D)• Give fluid challenges of 1000 ml of crystalloids or 300–500 ml of colloids over 30 min. More rapid and larger volumes may be required
in sepsis-induced tissue hypoperfusion. (1D)• Rate of fluid administration should be reduced if cardiac filling pressures increase without concurrent hemodynamic improvement. (1D)
Vasopressors
• Maintain MAP ≥ 65 mm Hg. (1C)• Norepinephrine or dopamine centrally administered are the initial vasopressors of choice. (1C)◦ Epinephrine, phenylephrine or vasopressin should not be administered as the initial vasopressor in septic shock. (2C)
– Vasopressin 0.03 units/min maybe subsequently added to norepinephrine with anticipation of an effect
equivalent to norepinephrine alone.
◦ Use epinephrine as the first alternative agent in septic shock when blood pressure is poorly responsive to norepinephrine
or dopamine. (2B)• Do not use low-dose dopamine for renal protection. (1A)• In patients requiring vasopressors, insert an arterial catheter as soon as practical. (1D)
Inotropic therapy
• Use dobutamine in patients with myocardial dysfunction as supported by elevated cardiac filling pressures and low cardiac output. (1C)• Do not increase cardiac index to predetermined supranormal levels. (1B)
Steroids
◦ Consider intravenous hydrocortisone for adult septic shock when hypotension remains poorly responsive to adequate
fluid resuscitation and vasopressors. (2C)◦ ACTH stimulation test is not recommended to identify the subset of adults with septic shock who should receive hydrocortisone. (2B)◦ Hydrocortisone is preferred to dexamethasone. (2B)◦ Fludrocortisone (50 µg orally once a day) may be included if an alternative to hydrocortisone is being used which lacks significant
mineralocorticoid activity. Fludrocortisone is optional if hydrocortisone is used. (2C)◦ Steroid therapy may be weaned once vasopressors are no longer required. (2D)• Hydrocortisone dose should be ≤ 300 mg/day. (1A)• Do not use corticosteroids to treat sepsis in the absence of shock unless the patient’s endocrine or corticosteroid history warrants it. (1D)
Recombinant human activated protein C (rhAPC)
◦ Consider rhAPC in adult patients with sepsis-induced organ dysfunction with clinical assessment of high risk of death
(typically APACHE II ≥ 25 or multiple organ failure) if there are no contraindications. (2B,2Cfor post-operative patients)• Adult patients with severe sepsis and low risk of death (e. g.: APACHE II<20 or one organ failure) should not receive rhAPC. (1A)
of central venous and mixed venous oxygen saturation
targets to be equivalent. Either intermittent or continuous
measurements of oxygen saturation were judged to be
acceptable. Although blood lactate concentration may
lack precision as a measure of tissue metabolic status,
elevated levels in sepsis support aggressive resuscitation.
In mechanically ventilated patients or patients with
known pre-existing decreased ventricular compliance,
a higher target CVP of 12–15 mm Hg is recommended
to account for the impediment to filling [17]. Simi-
lar consideration may be warranted in circumstances
of increased abdominal pressure or diastolic dysfunc-
tion [18]. Elevated central venous pressures may also be
seen with pre-existing clinically significant pulmonary
artery hypertension. Although the cause of tachycardia
in septic patients may be multifactorial, a decrease in
elevated pulse rate with fluid resuscitation is often a use-
ful marker of improving intravascular filling. Recently
published observational studies have demonstrated an
association between good clinical outcome in septic
shock and MAP ≥ 65 mm Hg as well as central ve-
nous oxygen saturation (ScvO2, measured in superior
vena cava, either intermittently or continuously) of
≥ 70% [19]. Many recent studies support the value of
early protocolized resuscitation in severe sepsis and
sepsis-induced tissue hypoperfusion [20–25]. Studies
of patients with shock indicate that SvO2 runs 5–7%
lower than central venous oxygen saturation (ScvO2) [26]
and that an early goal directed resuscitation protocol
can be established in a non-research general practice
venue [27].
There are recognized limitations to ventricular filling
pressure estimates as surrogates for fluid resuscita-
tion [28, 29]. However, measurement of CVP is currently
the most readily obtainable target for fluid resuscitation.
There may be advantages to targeting fluid resuscitation
to flow and perhaps to volumetric indices (and even
to microcirculation changes) [30–33]. Technologies
currently exist that allow measurement of flow at the
bedside [34, 35]. Future goals should be making these
technologies more accessible during the critical early
resuscitation period and research to validate utility.
These technologies are already available for early ICU
resuscitation.
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Table 5 Other Supportive Therapy of Severe Sepsis
Blood product administration
Strength of recommendation and quality of evidence have been assessed using the GRADE criteria, presented in brackets after each guide-
line. For added clarity: • Indicates a strong recommendation or “we recommend”; ◦ indicates a weak recommendation or “we suggest”
• Give red blood cells when hemoglobin decreases to < 7.0 g/dl (< 70 g/L) to target a hemoglobin of 7.0–9.0 g/dl in adults. (1B)
– A higher hemoglobin level may be required in special circumstances (e. g.: myocardial ischaemia, severe hypoxemia, acute
haemorrhage, cyanotic heart disease or lactic acidosis)
• Do not use erythropoietin to treat sepsis-related anemia. Erythropoietin may be used for other accepted reasons. (1B)• Do not use fresh frozen plasma to correct laboratory clotting abnormalities unless there is bleeding or planned invasive procedures. (2D)◦ Do not use antithrombin therapy. (1B)• Administer platelets when: (2D)
– counts are < 5000/mm3 (5 × 109/L) regardless of bleeding.
– counts are 5000 to 30,000/mm3 (5–30 × 109/L) and there is significant bleeding risk.
– Higher platelet counts (≥ 50,000/mm3 (50 × 109/L)) are required for surgery or invasive procedures.
Mechanical ventilation of sepsis-induced acute lung injury (ALI)/ARDS
• Target a tidal volume of 6 ml/kg (predicted) body weight in patients with ALI/ARDS. (1B)• Target an initial upper limit plateau pressure ≤ 30 cm H2O. Consider chest wall compliance when assessing plateau pressure. (1C)• Allow PaCO2 to increase above normal, if needed to minimize plateau pressures and tidal volumes. (1C)• Positive end expiratory pressure (PEEP) should be set to avoid extensive lung collapse at end expiration. (1C)◦ Consider using the prone position for ARDS patients requiring potentially injurious levels of FiO2 or plateau pressure,
provided they are not put at risk from positional changes. (2C)• Maintain mechanically ventilated patients in a semi-recumbent position (head of the bed raised to 45 ◦) unless contraindicated (1B),
between 30◦–45◦ (2C).◦ Non invasive ventilation may be considered in the minority of ALI/ARDS patients with mild-moderate hypoxemic respiratory failure.
The patients need to be hemodynamically stable, comfortable, easily arousable, able to protect/clear their airway and expected
to recover rapidly. (2B)• Use a weaning protocol and a spontaneous breathing trial (SBT) regularly to evaluate the potential for discontinuing
mechanical ventilation. (1A)
– SBT options include a low level of pressure support with continuous positive airway pressure 5 cm H2O or a T-piece.
– Before the SBT, patients should:
– be arousable
– be haemodynamically stable without vasopressors
– have no new potentially serious conditions
– have low ventilatory and end-expiratory pressure requirement
– require FiO2 levels that can be safely delivered with a face mask or nasal cannula• Do not use a pulmonary artery catheter for the routine monitoring of patients with ALI/ARDS. (1A)• Use a conservative fluid strategy for patients with established ALI who do not have evidence of tissue hypoperfusion. (1C)
Sedation, analgesia, and neuromuscular blockade in sepsis
• Use sedation protocols with a sedation goal for critically ill mechanically ventilated patients. (1B)• Use either intermittent bolus sedation or continuous infusion sedation to predetermined end points (sedation scales), with daily
interruption/lightening to produce awakening. Re-titrate if necessary. (1B)• Avoid neuromuscular blockers (NMBs) where possible. Monitor depth of block with train of four when using continuous infusions. (1B)
Glucose control
• Use IV insulin to control hyperglycemia in patients with severe sepsis following stabilization in the ICU. (1B)• Aim to keep blood glucose < 150 mg/dl (8.3 mmol/L) using a validated protocol for insulin dose adjustment. (2C)• Provide a glucose calorie source and monitor blood glucose values every 1–2 hrs (4 hrs when stable) in patients receiving
intravenous insulin. (1C)• Interpret with caution low glucose levels obtained with point of care testing, as these techniques may overestimate arterial blood
or plasma glucose values. (1B)
Renal replacement
◦ Intermittent hemodialysis and continuous veno-venous haemofiltration (CVVH) are considered equivalent. (2B)◦ CVVH offers easier management in hemodynamically unstable patients. (2D)
Bicarbonate therapy
• Do not use bicarbonate therapy for the purpose of improving hemodynamics or reducing vasopressor requirements when treating
hypoperfusion-induced lactic acidemia with pH ≥ 7.15. (1B)
Deep vein thrombosis (DVT) prophylaxis
• Use either low-dose unfractionated heparin (UFH) or low-molecular weight heparin (LMWH), unless contraindicated. (1A)• Use a mechanical prophylactic device, such as compression stockings or an intermittent compression device, when
heparin is contraindicated. (1A)◦ Use a combination of pharmacologic and mechanical therapy for patients who are at very high risk for DVT. (2C)◦ In patients at very high risk LMWH should be used rather than UFH. (2C)
Stress ulcer prophylaxis
• Provide stress ulcer prophylaxis using H2 blocker (1A) or proton pump inhibitor (1B). Benefits of prevention of upper GI bleed must
be weighed against the potential for development of ventilator-associated pneumonia.
Consideration for limitation of support
• Discuss advance care planning with patients and families. Describe likely outcomes and set realistic expectations. (1D)
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2. We suggest that during the first 6 hrs of resuscitation of
severe sepsis or septic shock, if SCVO2 or SvO2 of 70%
or 65% respectively is not achieved with fluid resusci-
tation to the CVP target, then transfusion of packed red
blood cells to achieve a hematocrit of ≥ 30% and/or
administration of a dobutamine infusion (up to a max-
imum of 20 µg.kg–1.min–1) be utilized to achieve this
goal (Grade 2C).
Rationale. The protocol used in the study cited previously
targeted an increase in SCVO2 to ≥ 70% [16]. This was
achieved by sequential institution of initial fluid resusci-
tation, then packed red blood cells, and then dobutamine.
This protocol was associated with an improvement
in survival. Based on bedside clinical assessment and
personal preference, a clinician may deem either blood
transfusion (if Hct is less than 30%) or dobutamine the
best initial choice to increase oxygen delivery and thereby
elevate SCVO2. When fluid resuscitation is believed to
be already adequate. The design of the afore mentioned
trial did not allow assessment of the relative contribution
of these two components (i. e. increasing O2 content or
increasing cardiac output) of the protocol on achievement
of improved outcome.
B. Diagnosis
1. We recommend obtaining appropriate cultures before
antimicrobial therapy is initiated if such cultures do not
cause significant delay in antibiotic administration. To
optimize identification of causative organisms, we rec-
ommend at least two blood cultures be obtained prior to
antibiotics with at least one drawn percutaneously and
one drawn through each vascular access device, unless
the device was recently (< 48 h) inserted. Cultures of
other sites (preferably quantitative where appropriate)
such as urine, cerebrospinal fluid, wounds, respiratory
secretions, or other body fluids that may be the source
of infection should also be obtained before antibiotic
therapy if not associated with significant delay in anti-
biotic administration (Grade 1C).
Rationale. Although sampling should not delay timely
administration of antibiotics in patients with severe sepsis
(example: lumbar puncture in suspected meningitis),
obtaining appropriate cultures prior to their administration
is essential to confirm infection and the responsible
pathogen(s), and to allow de-escalation of antibiotic
therapy after receipt of the susceptibility profile. Samples
can be kept in the refrigerator or frozen if processing
cannot be performed immediately. Immediate transport to
a microbiological lab is necessary. Because rapid steriliza-
tion of blood cultures can occur within a few hours after
the first antibiotic dose, obtaining those cultures before
starting therapy is essential if the causative organism is
to be identified. Two or more blood cultures are recom-
mended [36]. In patients with indwelling catheters (for
> 48 h) at least one blood culture should be drawn through
each lumen of each vascular access device. Obtaining
blood cultures peripherally and through a vascular access
device is an important strategy. If the same organism
is recovered from both cultures, the likelihood that the
organism is causing the severe sepsis is enhanced. In
addition, if the culture drawn through the vascular ac-
cess device is positive much earlier than the peripheral
blood culture (i. e., > 2 hrs earlier), the data support the
concept that the vascular access device is the source of
the infection [37]. Quantitative cultures of catheter and
peripheral blood are also useful for determining whether
the catheter is the source of infection. Volume of blood
drawn with the culture tube should be at least 10 mL [38].
Quantitative (or semi-quantitative) cultures of respiratory
tract secretions are recommended for the diagnosis of
ventilator-associated pneumonia [39]. Gram stain can
be useful, in particular for respiratory tract specimens,
to help decide the micro-organisms to be targeted. The
potential role of biomarkers for diagnosis of infection in
patients presenting with severe sepsis remains at present
undefined. The procalcitonin level, although often useful,
is problematic in patients with an acute inflammatory
pattern from other causes (e. g. post-operative, shock) [40]
In the near future, rapid diagnostic methods (polymerase
chain reaction, micro-arrays) might prove extremely
helpful for a quicker identification of pathogens and major
antimicrobial resistance determinants [41].
2. We recommend that imaging studies be performed
promptly in attempts to confirm a potential source of
infection. Sampling of potential sources of infection
should occur as they are identified; however, some
patients may be too unstable to warrant certain in-
vasive procedures or transport outside of the ICU.
Bedside studies, such as ultrasound, are useful in these
circumstances (Grade 1C).
Rationale. Diagnostic studies may identify a source of
infection that requires removal of a foreign body or drain-
age to maximize the likelihood of a satisfactory response
to therapy. However, even in the most organized and
well-staffed healthcare facilities, transport of patients
can be dangerous, as can placing patients in outside-unit
imaging devices that are difficult to access and monitor.
Balancing risk and benefit is therefore mandatory in those
settings.
C. Antibiotic Therapy
1. We recommend that intravenous antibiotic therapy
be started as early as possible and within the first
hour of recognition of septic shock (1B) and severe
sepsis without septic shock (1D). Appropriate cultures
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should be obtained before initiating antibiotic therapy,
but should not prevent prompt administration of
antimicrobial therapy (Grade 1D).
Rationale. Establishing vascular access and initiating
aggressive fluid resuscitation is the first priority when
managing patients with severe sepsis or septic shock.
However, prompt infusion of antimicrobial agents should
also be a priority and may require additional vascular
access ports [42, 43]. In the presence of septic shock
each hour delay in achieving administration of effective
antibiotics is associated with a measurable increase in
mortality [42]. If antimicrobial agents cannot be mixed
and delivered promptly from the pharmacy, establishing
a supply of premixed antibiotics for such urgent situations
is an appropriate strategy for ensuring prompt adminis-
tration. In choosing the antimicrobial regimen, clinicians
should be aware that some antimicrobial agents have the
advantage of bolus administration, while others require
a lengthy infusion. Thus, if vascular access is limited and
many different agents must be infused, bolus drugs may
offer an advantage.
2a. We recommend that initial empirical anti-infective
therapy include one or more drugs that have activity
against all likely pathogens (bacterial and/or fungal)
and that penetrate in adequate concentrations into the
presumed source of sepsis (Grade 1B).
Rationale. The choice of empirical antibiotics depends
on complex issues related to the patient’s history includ-
ing drug intolerances, underlying disease, the clinical
syndrome, and susceptibility patterns of pathogens in
the community, in the hospital, and that previously have
been documented to colonize or infect the patient. There
is an especially wide range of potential pathogens for
neutropenic patients.
Recently used antibiotics should generally be avoided.
Clinicians should be cognizant of the virulence and
growing prevalence of oxacillin (methicillin) resistant
Staphylococcus aureus (ORSA or MRSA) in some com-
munities and healthcare associated settings (especially in
the United States) when they choose empiric therapy. If
the prevalence is significant, and in consideration of the
virulence of this organism, empiric therapy adequate for
this pathogen would be warranted. Clinicians should also
consider whether Candidemia is a likely pathogen when
choosing initial therapy. When deemed warranted, the
selection of empiric antifungal therapy (e. g., fluconazole,
amphotericin B, or echinocandin) will be tailored to the
local pattern of the most prevalent Candida species, and
any prior administration of azoles drugs [44]. Risk factors
for candidemia should also be considered when choosing
initial therapy.
Because patients with severe sepsis or septic shock
have little margin for error in the choice of therapy,
the initial selection of antimicrobial therapy should be
broad enough to cover all likely pathogens. There is
ample evidence that failure to initiate appropriate therapy
(i. e. therapy with activity against the pathogen that is
subsequently identified as the causative agent) correlates
with increased morbidity and mortality [45–48].
Patients with severe sepsis or septic shock warrant
broad-spectrum therapy until the causative organism
and its antibiotic susceptibilities are defined. Restriction
of antibiotics as a strategy to reduce the development
of antimicrobial resistance or to reduce cost is not an
appropriate initial strategy in this patient population.
All patients should receive a full loading dose of each
antimicrobial. However, patients with sepsis or septic
shock often have abnormal renal or hepatic function
and may have abnormal volumes of distribution due to
aggressive fluid resuscitation. Drug serum concentration
monitoring can be useful in an ICU setting for those drugs
that can be measured promptly. An experienced physician
or clinical pharmacist should be consulted to ensure that
serum concentrations are attained that maximize efficacy
and minimize toxicity [49–52].
2b. We recommend that the antimicrobial regimen be re-
assessed daily to optimize activity, to prevent the de-
velopment of resistance, to reduce toxicity, and to re-
duce costs (Grade 1C).
Rationale. Although restriction of antibiotics as a strategy
to reduce the development of antimicrobial resistance
or to reduce cost is not an appropriate initial strategy
in this patient population, once the causative pathogen
has been identified, it may become apparent that none
of the empiric drugs offers optimal therapy; i. e., there
may be another drug proven to produce superior clin-
ical outcome which should therefore replace empiric
agents.
Narrowing the spectrum of antibiotic coverage and re-
ducing the duration of antibiotic therapy will reduce the
likelihood that the patient will develop superinfection with
pathogenic or resistant organisms such as Candida species,
Clostridium difficile, or vancomycin-resistant Enterococ-
cus faecium. However, the desire to minimize superinfec-
tions and other complications should not take precedence
over the need to give the patient an adequate course of ther-
apy to cure the infection that caused the severe sepsis or
septic shock.
2c. We suggest combination therapy for patients with
known or suspected Pseudomonas infections as
a cause of severe sepsis (Grade 2D).
2d. We suggest combination empiric therapy for neu-
tropenic patients with severe sepsis (Grade 2D).
2e. When used empirically in patients with severe sepsis,
we suggest that combination therapy should not be ad-
ministered for more than 3 to 5 days. De-escalation
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to the most appropriate single therapy should be per-
formed as soon as the susceptibility profile is known.
(Grade 2D).
Rationale. Although no study or meta-analysis has con-
vincingly demonstrated that combination therapy produces
a superior clinical outcome for individual pathogens in
a particular patient group, combination therapies do
produce in vitro synergy against pathogens in some
models (although such synergy is difficult to define and
predict). In some clinical scenarios, such as the two above,
combination therapies are biologically plausible and are
likely clinically useful even if evidence has not demon-
strated improved clinical outcome [53–56]. Combination
therapy for suspected known Pseudomonas pending
sensitivities increases the likelihood that at least one drug
is effective against that strain and positively affects out-
come [57].
3. We recommend that the duration of therapy typically
be 7–10 days; longer courses may be appropriate in pa-
tients who have a slow clinical response, undrainable
foci of infection, or who have immunologic deficien-
cies including neutropenia (Grade 1D).
4. If the presenting clinical syndrome is determined to be
due to a noninfectious cause, we recommend antimi-
crobial therapy be stopped promptly to minimize the
likelihood that the patient will become infected with
an antibiotic resistant pathogen or will develop a drug
related adverse effect (Grade 1D).
Rationale. Clinicians should be cognizant that blood cul-
tures will be negative in more than 50% of cases of se-
vere sepsis or septic shock, yet many of these cases are
very likely caused by bacteria or fungi. Thus, the decisions
to continue, narrow, or stop antimicrobial therapy must be
made on the basis of clinician judgment and clinical infor-
mation.
D. Source Control
1a. We recommend that a specific anatomic diagnosis
of infection requiring consideration for emergent
source control- for example necrotizing fasciitis,
diffuse peritonitis, cholangitis, intestinal infarction
– be sought and diagnosed or excluded as rapidly
as possible (Grade 1C) and within the first 6 hours
following presentation (Grade 1D).
1b. We further recommend that all patients presenting
with severe sepsis be evaluated for the presence
of a focus of infection amenable to source control
measures, specifically the drainage of an abscess
or local focus of infection, the debridement of in-
fected necrotic tissue, the removal of a potentially
infected device, or the definitive control of a source
of ongoing microbial contamination (Grade 1C) (see
Appendix A for examples of potential sites needing
source control).
2. We suggest that when infected peripancreatic necrosis
is identified as a potential source of infection, defini-
tive intervention is best delayed until adequate demar-
cation of viable and non-viable tissues has occurred
(Grade 2B).
3. We recommend that when source control is required,
the effective intervention associated with the least
physiologic insult be employed e. g., percutaneous
rather than surgical drainage of an abscess (Grade
1D).
4. We recommend that when intravascular access
devices are a possible source of severe sepsis or septic
shock, they be promptly removed after establishing
other vascular access (Grade 1C).
Rationale. The principles of source control in the man-
agement of sepsis include a rapid diagnosis of the
specific site of infection, and identification of a focus of
infection amenable to source control measures (specif-
ically the drainage of an abscess, the debridement of
infected necrotic tissue, the removal of a potentially
infected device, and the definitive control of a source
of ongoing microbial contamination) [58]. Foci of in-
fection readily amenable to source control measures
include an intra-abdominal abscess or gastrointestinal
perforation, cholangitis or pyelonephritis, intestinal is-
chemia or necrotizing soft tissue infection, and other
deep space infection such as an empyema or septic
arthritis. Such infectious foci should be controlled as
soon as possible following successful initial resuscita-
tion [59], accomplishing the source control objective
with the least physiologic upset possible (e. g., percuta-
neous rather than surgical drainage of an abscess [60],
endoscopic rather than surgical drainage of biliary
tree), and removing intravascular access devices that
are potentially the source of severe sepsis or septic
shock promptly after establishing other vascular ac-
cess [61, 62]. A randomized, controlled trial comparing
early vs. delayed surgical intervention for peripancre-
atic necrosis showed better outcomes with a delayed
approach [63]. However, areas of uncertainty, such as
definitive documentation of infection and appropriate
length of delay exist. The selection of optimal source
control methods must weigh benefits and risks of the
specific intervention as well as risks of transfer [64].
Source control interventions may cause further compli-
cations such as bleeding, fistulas, or inadvertent organ
injury. Surgical intervention should be considered when
lesser interventional approaches are inadequate, or when
diagnostic uncertainty persists despite radiological eval-
uation. Specific clinical situations require consideration
of available choices, patient’s preferences, and clinician’s
expertise.
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E. Fluid Therapy
1. We recommend fluid resuscitation with either nat-
ural/artificial colloids or crystalloids. There is no
evidence-based support for one type of fluid over
another (Grade 1B).
Rationale. The SAFE study indicated albumin adminis-
tration was safe and equally effective as crystalloid [65].
There was an insignificant decrease in mortality rates with
the use of colloid in a subset analysis of septic patients
(p = 0.09). Previous meta-analyses of small studies of ICU
patients had demonstrated no difference between crystal-
loid and colloid fluid resuscitation [66–68]. Although ad-
ministration of hydroxyethyl starch may increase the risk
of acute renal failure in patients with sepsis variable find-
ings preclude definitive recommendations [69, 70]. As the
volume of distribution is much larger for crystalloids than
for colloids, resuscitation with crystalloids requires more
fluid to achieve the same end points and results in more
edema. Crystalloids are less expensive.
2. We recommend fluid resuscitation initially target
a CVP of at least 8 mm Hg (12 mm Hg in mechani-
cally ventilated patients). Further fluid therapy is often
required (Grade 1C).
3a. We recommend that a fluid challenge technique be
applied, wherein fluid administration is continued
as long as the hemodynamic improvement (e. g.,
arterial pressure, heart rate, urine output) continues
(Grade 1D).
3b. We recommend fluid challenge in patients with
suspected hypovolemia be started with at least
1000 mL of crystalloids or 300–500 mL of colloids
over 30 min. More rapid administration and greater
amounts of fluid may be needed in patients with sepsis
induced tissue hypoperfusion (see initial resuscitation
recommendations) (Grade 1D).
3c. We recommend the rate of fluid administration be
reduced substantially when cardiac filling pressures
(CVP or pulmonary artery balloon-occluded pres-
sure) increase without concurrent hemodynamic
improvement (Grade 1D).
Rationale. Fluid challenge must be clearly separated from
simple fluid administration; it is a technique in which large
amounts of fluids are administered over a limited period
of time under close monitoring to evaluate the patient’s re-
sponse and avoid the development of pulmonary edema.
The degree of intravascular volume deficit in patients with
severe sepsis varies. With venodilation and ongoing capil-
lary leak, most patients require continuing aggressive fluid
resuscitation during the first 24 hours of management. In-
put is typically much greater than output, and input/output
ratio is of no utility to judge fluid resuscitation needs dur-
ing this time period.
F. Vasopressors
1. We recommend mean arterial pressure (MAP) be
maintained ≥ 65 mm Hg (Grade 1C).
Rationale. Vasopressor therapy is required to sustain life
and maintain perfusion in the face of life-threatening
hypotension, even when hypovolemia has not yet been
resolved. Below a certain mean arterial pressure, autoreg-
ulation in various vascular beds can be lost, and perfusion
can become linearly dependent on pressure. Thus, some
patients may require vasopressor therapy to achieve
a minimal perfusion pressure and maintain adequate
flow [71, 72]. The titration of norepinephrine to as low
as MAP 65 mm Hg has been shown to preserve tissue
perfusion [72]. In addition, pre-existing comorbidities
should be considered as to most appropriate MAP target.
For example, a MAP of 65 mm Hg might be too low in
a patient with severe uncontrolled hypertension, and in
a young previously normotensive, a lower MAP might
be adequate. Supplementing end points such as blood
pressure with assessment of regional and global perfusion,
such as blood lactate concentrations and urine output, is
important. Adequate fluid resuscitation is a fundamental
aspect of the hemodynamic management of patients with
septic shock, and should ideally be achieved before vaso-
pressors and inotropes are used, but using vasopressors
early as an emergency measure in patients with severe
shock is frequently necessary. When that occurs great
effort should be directed to weaning vasopressors with
continuing fluid resuscitation.
2. We recommend either norepinephrine or dopamine as
the first choice vasopressor agent to correct hypoten-
sion in septic shock (administered through a central
catheter as soon as one is available) (Grade 1C).
3a. We suggest that epinephrine, phenylephrine, or
vasopressin should not be administered as the initial
vasopressor in septic shock (Grade 2C). Vasopressin
.03 units/min may be subsequently added to nore-
pinephrine with anticipation of an effect equivalent to
norepinephrine alone.
3b. We suggest that epinephrine be the first chosen alter-
native agent in septic shock that is poorly responsive
to norepinephrine or dopamine (Grade 2B).
Rationale. There is no high-quality primary evidence to
recommend one catecholamine over another. Much litera-
ture exists that contrasts the physiologic effects of choice
of vasopressor and combined inotrope/vasopressors in
septic shock [73–85]. Human and animal studies suggest
some advantages of norepinephrine and dopamine over
epinephrine (the latter with the potential for tachycardia as
well as disadvantageous effects on splanchnic circulation
and hyperlactemia) and phenylephrine (decrease in stroke
volume). There is, however, no clinical evidence that
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epinephrine results in worse outcomes, and it should be
the first chosen alternative to dopamine or norepinephrine.
Phenylephrine is the adrenergic agent least likely to
produce tachycardia, but as a pure vasopressor would be
expected to decrease stroke volume. Dopamine increases
mean arterial pressure and cardiac output, primarily
due to an increase in stroke volume and heart rate.
Norepinephrine increases mean arterial pressure due to
its vasoconstrictive effects, with little change in heart
rate and less increase in stroke volume compared with
dopamine. Either may be used as a first-line agent to cor-
rect hypotension in sepsis. Norepinephrine is more potent
than dopamine and may be more effective at reversing
hypotension in patients with septic shock. Dopamine
may be particularly useful in patients with compromised
systolic function but causes more tachycardia and may
be more arrhythmogenic [86]. It may also influence the
endocrine response via the hypothalamic-pituitary axis
and have immunosuppressive effects.
Vasopressin levels in septic shock have been reported
to be lower than anticipated for a shock state [87]. Low
doses of vasopressin may be effective in raising blood
pressure in patients refractory to other vasopressors, and
may have other potential physiologic benefits [88–93].
Terlipressin has similar effects but is long lasting [94].
Studies show that vasopressin concentrations are elevated
in early septic shock, but with continued shock, con-
centration decreases to normal range in the majority of
patients between 24 and 48 hrs [95]. This has been called
“relative vasopressin deficiency” because in the presence
of hypotension, vasopressin would be expected to be
elevated. The significance of this finding is unknown.
The recent VASST trial, a randomized, controlled trial
comparing norepinephrine alone to norepinephrine plus
vasopressin at .03 units per minute showed no difference
in outcome in the intent to treat population. An a priori
defined subgroup analysis showed that the survival of
patients receiving less than 15 µg/min norepinephrine at
the time of randomization was better with vasopressin. It
should be noted however that the pre-trial rationale for
this stratification was based on exploring potential benefit
in the 15 µg or greater norepinephrine requirement popu-
lation. Higher doses of vasopressin have been associated
with cardiac, digital, and splanchnic ischemia and should
be reserved for situations where alternative vasopressors
have failed [96]. Cardiac output measurement to allow
maintenance of a normal or elevated flow is desirable
when these pure vasopressors are instituted.
5. We recommend that low dose dopamine not be used
for renal protection (Grade 1A).
Rationale. A large randomized trial and meta-analysis
comparing low-dose dopamine to placebo found no differ-
ence in either primary outcomes (peak serum creatinine,
need for renal replacement, urine output, time to recovery
of normal renal function), or secondary outcomes (survival
to either ICU or hospital discharge, ICU stay, hospital
stay, arrhythmias) [97, 98]. Thus the available data do not
support administration of low doses of dopamine solely to
maintain renal function.
6. We recommend that all patients requiring vasopressors
have an arterial line placed as soon as practical if re-
sources are available (Grade 1D).
Rationale. In shock states, estimation of blood pressure
using a cuff is commonly inaccurate; use of an arterial can-
nula provides a more appropriate and reproducible meas-
urement of arterial pressure. These catheters also allow
continuous analysis so that decisions regarding therapy can
be based on immediate and reproducible blood pressure in-
formation.
G. Inotropic Therapy
1. We recommend a dobutamine infusion be adminis-
tered in the presence of myocardial dysfunction as
suggested by elevated cardiac filling pressures and low
cardiac output (Grade 1C).
2. We recommend against the use of a strategy to
increase cardiac index to predetermined supranormal
levels (Grade 1B).
Rationale. Dobutamine is the first-choice inotrope for
patients with measured or suspected low cardiac output in
the presence of adequate left ventricular filling pressure (or
clinical assessment of adequate fluid resuscitation) and ad-
equate mean arterial pressure. Septic patients who remain
hypotensive after fluid resuscitation may have low, normal,
or increased cardiac outputs. Therefore, treatment with
a combined inotrope/vasopressor such as norepinephrine
or dopamine is recommended if cardiac output is not mea-
sured. When the capability exists for monitoring cardiac
output in addition to blood pressure, a vasopressor such as
norepinephrine may be used separately to target specific
levels of mean arterial pressure and cardiac output. Two
large prospective clinical trials that included critically ill
ICU patients who had severe sepsis failed to demonstrate
benefit from increasing oxygen delivery to supranormal
targets by use of dobutamine [99, 100]. These studies
did not target specifically patients with severe sepsis and
did not target the first 6 hours of resuscitation. The first
6 hours of resuscitation of sepsis induced hypoperfusion
need to be treated separately from the later stages of severe
sepsis (see initial resuscitation recommendations).
H. Corticosteroids
1. We suggest intravenous hydrocortisone be given only
to adult septic shock patients after blood pressure is
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identified to be poorly responsive to fluid resuscitation
and vasopressor therapy (Grade 2C).
Rationale. One french multi-center, randomized, con-
trolled trial (RCT) of patients in vasopressor-unresponsive
septic shock (hypotension despite fluid resuscitation
and vasopressors) showed a significant shock reversal
and reduction of mortality rate in patients with relative
adrenal insufficiency (defined as post-adrenocorticotropic
hormone (ACTH) cortisol increase 9 µg/dL or less) [101].
Two additional smaller RCTs also showed significant
effects on shock reversal with steroid therapy [102, 103].
However, a recent large, European multicenter trial (COR-
TICUS), which has been presented in abstract form but
not yet published, failed to show a mortality benefit with
steroid therapy of septic shock [104]. CORTICUS did
show a faster resolution of septic shock in patients who
received steroids. The use of the ACTH test (responders
and nonresponders) did not predict the faster resolution
of shock. Importantly, unlike the French trial, which
only enrolled shock patients with blood pressure unre-
sponsive to vasopressor therapy, the CORTICUS study
included patients with septic shock, regardless of how
the blood pressure responded to vasopressors. Although
corticosteroids do appear to promote shock reversal, the
lack of a clear improvement in mortality-coupled with
known side effects of steroids such as increased risk of
infection and myopathy-generally tempered enthusiasm
for their broad use. Thus, there was broad agreement
that the recommendation should be downgraded from the
previous guidelines (Appendix B). There was considerable
discussion and consideration by the committee on the
option of encouraging use in those patients whose blood
pressure was unresponsive to fluids and vasopressors,
while strongly discouraging use in subjects whose shock
responded well to fluids and pressors. However, this more
complex set of recommendations was rejected in favor of
the above single recommendation (see Appendix B).
2. We suggest the ACTH stimulation test not be used
to identify the subset of adults with septic shock who
should receive hydrocortisone (Grade 2B).
Rationale. Although one study suggested those who did
not respond to ACTH with a brisk surge in cortisol (failure
to achieve or > 9 µg/dL increase in cortisol 30–60 mins
post-ACTH administration) were more likely to benefit
from steroids than those who did respond, the overall
trial population appeared to benefit regardless of ACTH
result, and the observation of a potential interaction
between steroid use and ACTH test was not statistically
significant [101]. Furthermore, there was no evidence of
this distinction between responders and nonresponders in
a recent multicenter trial [104]. Commonly used cortisol
immunoassays measure total cortisol (protein-bound and
free) while free cortisol is the pertinent measurement.
The relationship between free and total cortisol varies
with serum protein concentration. When compared to
a reference method (mass spectrometry), cortisol im-
munoassays may over- or underestimate the actual cortisol
level, affecting the assignment of patients to responders
or nonresponders [105]. Although the clinical significance
is not clear, it is now recognized that etomidate, when
used for induction for intubation, will suppress the HPA
axis [106].
3. We suggest that patients with septic shock should not
receive dexamethasone if hydrocortisone is available
(Grade 2B).
Rationale. Although often proposed for use until an ACTH
stimulation test can be administered, we no longer sug-
gest an ACTH test in this clinical situation (see #3 above).
Furthermore, dexamethasone can lead to immediate and
prolonged suppression of the HPA axis after administra-
tion [107].
4. We suggest the daily addition of oral fludrocortisone
(50 µg) if hydrocortisone is not available and the
steroid that is substituted has no significant minera-
locorticoid activity. Fludrocortisone is considered
optional if hydrocortisone is used (Grade 2C).
Rationale. One study added 50 µg of fludrocortisone
orally [101]. Since hydrocortisone has intrinsic miner-
alcorticoid activity, there is controversy as to whether
fludrocortisone should be added.
5. We suggest clinicians wean the patient from steroid
therapy when vasopressors are no longer required
(Grade 2D).
Rationale. There has been no comparative study between
a fixed duration and clinically guided regimen, or between
tapering and abrupt cessation of steroids. Three RCTs used
a fixed duration protocol for treatment [101, 103, 104],
and in two RCTs, therapy was decreased after shock reso-
lution [102, 108]. In four RCTs steroids were tapered over
several days [102–104, 108], and in two RCTs [101, 109]
steroids were withdrawn abruptly. One cross-over study
showed hemodynamic and immunologic rebound effects
after abrupt cessation of corticosteroids [110]. It remains
uncertain whether outcome is affected by tapering of
steroids or not.
6. We recommend doses of corticosteroids comparable
to > 300 mg hydrocortisone daily not be used in severe
sepsis or septic shock for the purpose of treating septic
shock (Grade 1A).
Rationale. Two randomized prospective clinical trials and
a meta-analyses concluded that for therapy of severe sepsis
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or septic shock, high-dose corticosteroid therapy is inef-
fective or harmful [111–113]. Reasons to maintain higher
doses of corticosteroid for medical conditions other than
septic shock may exist.
7. We recommend corticosteroids not be administered
for the treatment of sepsis in the absence of shock.
There is, however, no contraindication to continuing
maintenance steroid therapy or to using stress does
steroids if the patient’s endocrine or corticosteroid
administration history warrants (Grade 1D).
Rationale. No studies exist that specifically target severe
sepsis in the absence of shock that offer support for use
of stress doses of steroids in this patient population.
Steroids may be indicated in the presence of a prior
history of steroid therapy or adrenal dysfunction. A re-
cent preliminary study of stress dose level steroids in
community- acquired pneumonia is encouraging but needs
confirmation [114].
I. Recombinant Human Activated Protein C (rhAPC)
1. We suggest that adult patients with sepsis induced
organ dysfunction associated with a clinical assess-
ment of high risk of death, most of whom will have
APACHE II ≥ 25 or multiple organ failure, receive
rhAPC if there are no contraindications (Grade 2B
except for patients within 30 days of surgery where it
is Grade 2C). Relative contraindications should also
be considered in decision making.
2. We recommend that adult patients with severe sep-
sis and low risk of death, most of whom will have
APACHE II < 20 or one organ failure, do not receive
rhAPC (Grade 1A).
Rationale. The evidence concerning use of rhAPC in
adults is primarily based on two randomized controlled
trials (RCTs): PROWESS (1,690 adult patients, stopped
early for efficacy) [115] and ADDRESS (stopped early for
futility) [116]. Additional safety information comes from
an open-label observational study ENHANCE [117]. The
ENHANCE trial also suggested early administration of
rhAPC was associated with better outcomes.
PROWESS involved 1,690 patients and documented
6.1% in absolute total mortality reduction with a relative
risk reduction (RRR) of 19.4%, 95% CI 6.6–30.5%,
number needed to treat (NNT):16 [115]. Controversy
associated with the results focused on a number of sub-
group analyses. Subgroup analyses have the potential to
mislead due to the absence of an intent to treat, sampling
bias, and selection error [118]. The analyses suggested
increasing absolute and relative risk reduction with greater
risk of death using both higher APACHE II scores and
greater number of organ failures [119]. This led to drug
approval for patients with high risk of death (such as
APACHE II ≥ 25) and more than one organ failure in
Europe.
The ADDRESS trial involved 2,613 patients judged to
have a low risk of death at the time of enrollment. 28 day
mortality from all causes was 17% on placebo vs. 18.5%
on APC, relative risk (RR) 1.08, 95% CI 0.92–1.28 [116].
Again, debate focused on subgroup analyses; analyses re-
stricted to small subgroups of patients with APACHE II
score over 25, or more than one organ failures which failed
to show benefit; however these patient groups also had
a lower mortality than in PROWESS.
Relative risk reduction of death was numerically lower
in the subgroup of patients with recent surgery (n = 502) in
the PROWESS trial (30.7% placebo vs. 27.8% APC) [119]
when compared to the overall study population (30.8%
placebo vs. 24.7% APC) [115]. In the ADDRESS trial,
patients with recent surgery and single organ dysfunc-
tion who received APC had significantly higher 28 day
mortality rates (20.7% vs. 14.1%, p = 0.03, n = 635) [116].
Serious adverse events did not differ in the
studies [115–117] with the exception of serious bleeding,
which occurred more often in the patients treated with
APC: 2% vs. 3.5% (PROWESS; p = 0.06) [115]; 2.2% vs.
3.9% (ADDRESS; p < 0.01) [116]; 6.5% (ENHANCE,
open label) [117]. The pediatric trial and implications are
discussed in the pediatric consideration section of this
manuscript (see Appendix C for absolute contraindications
to use of rhAPC and prescribing information for relative
contraindications).
Intracranial hemorrhage (ICH) occurred in the
PROWESS trial in 0.1% (placebo) and 0.2% (APC)
(n. s.) [106], in the ADDRESS trial 0.4% (placebo) vs.
0.5% (APC) (n. s.) [116]; in ENHANCE 1.5% [108].
Registry studies of rhAPC report higher bleeding rates
than randomized controlled trials, suggesting that the risk
of bleeding in actual practice may be greater than reported
in PROWESS and ADDRESS [120, 121].
The two RCTs in adult patients were methodologically
strong, precise, and provide direct evidence regarding
death rates. The conclusions are limited, however, by
inconsistency that is not adequately resolved by subgroup
analyses (thus the designation of moderate quality evi-
dence). Results, however, consistently fail to show benefit
for the subgroup of patients at lower risk of death, and
consistently show increases in serious bleeding. The RCT
in pediatric severe sepsis failed to show benefit and has
no important limitations. Thus, for low risk and pediatric
patients, we rate the evidence as high quality.
For adult use there is probable mortality reduction in
patients with clinical assessment of high risk of death, most
of whom will have APACHE II ≥ 25 or multiple organ fail-
ure. There is likely no benefit in patients with low risk of
death, most of whom will have APACHE II < 20 or single
organ dysfunction. The effects in patients with more than
one organ failure but APACHE II < 25 are unclear and in
that circumstance one may use clinical assessment of the
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risk of death and number of organ failures to support de-
cision. There is a certain increased risk of bleeding with
administration of rhAPC which may be higher in surgical
patients and in the context of invasive procedures. Deci-
sion on utilization depends upon assessing likelihood of
mortality reduction versus increases in bleeding and cost
(see appendix D for nominal committee vote on recom-
mendation for rhAPC). A European Regulatory mandated
randomized controlled trial of rhAPC vs. placebo in pa-
tients with septic shock is now ongoing [122].
J. Blood Product Administration
1. Once tissue hypoperfusion has resolved and in
the absence of extenuating circumstances, such as
myocardial ischemia, severe hypoxemia, acute hem-
orrhage, cyanotic heart disease, or lactic acidosis
(see recommendations for initial resuscitation), we
recommend that red blood cell transfusion occur
when hemoglobin decreases to < 7.0 g/dL (< 70 g/L)
to target a hemoglobin of 7.0–9.0 g/dL (70–90 g/L) in
adults (Grade 1B).
Rationale. Although the optimum hemoglobin for patients
with severe sepsis has not been specifically investigated,
the Transfusion Requirements in Critical Care trial
suggested that a hemoglobin of 7–9 g/dL (70–90 g/L)
when compared to 10–12 g/dL (100–200 g/L) was not
associated with increased mortality rate in adults [123].
Red blood cell transfusion in septic patients increases
oxygen delivery but does not usually increase oxygen
consumption [124–126]. This transfusion threshold of
7 g/dL (70 g/L) contrasts with the early goal-directed
resuscitation protocol that uses a target hematocrit of 30%
in patients with low SCVO2 (measured in superior vena
cava) during the first 6 hrs of resuscitation of septic shock.
2. We recommend that erythropoietin not be used as
a specific treatment of anemia associated with severe
sepsis, but may be used when septic patients have other
accepted reasons for administration of erythropoietin
such as renal failure-induced compromise of red blood
cell production (Grade 1B).
Rationale. No specific information regarding erythro-
poietin use in septic patients is available, but clinical
trials in critically ill patients show some decrease in red
cell transfusion requirement with no effect on clinical
outcome [127, 128]. The effect of erythropoietin in severe
sepsis and septic shock would not be expected to be
more beneficial than in other critical conditions. Patients
with severe sepsis and septic shock may have coexisting
conditions that do warrant use of erythropoietin.
3. We suggest that fresh frozen plasma not be used to cor-
rect laboratory clotting abnormalities in the absence of
bleeding or planned invasive procedures (Grade 2D).
Rationale. Although clinical studies have not assessed the
impact of transfusion of fresh frozen plasma on outcomes
in critically ill patients, professional organizations have
recommended fresh frozen plasma for coagulopathy when
there is a documented deficiency of coagulation factors
(increased prothrombin time, international normalized
ratio, or partial thromboplastin time) and the presence
of active bleeding or before surgical or invasive proce-
dures [129–131]. In addition, transfusion of fresh frozen
plasma in nonbleeding patients with mild abnormalities of
prothrombin time usually fails to correct the prothrombin
time [132]. There are no studies to suggest that correction
of more severe coagulation abnormalities benefits patients
who are not bleeding.
4. We recommend against antithrombin administration
for the treatment of severe sepsis and septic shock
(Grade 1B).
Rationale. A phase III clinical trial of high-dose an-
tithrombin did not demonstrate any beneficial effect on
28-day all-cause mortality in adults with severe sepsis
and septic shock. High-dose antithrombin was associated
with an increased risk of bleeding when administered with
heparin [133]. Although a post hoc subgroup analysis of
patients with severe sepsis and high risk of death showed
better survival in patients receiving antithrombin, an-
tithrombin cannot be recommended at this time until
further clinical trials are performed [134].
5. In patients with severe sepsis, we suggest that platelets
should be administered when counts are < 5000/mm3
(5 × 109/L) regardless of apparent bleeding. Platelet
transfusion may be considered when counts are
5,000–30,000/mm3 (5–30 × 109/L) and there is
a significant risk of bleeding. Higher platelet counts
(≥ 50,000/mm3 (50 × 109/L)) are typically required
for surgery or invasive procedures (Grade 2D).
Rationale. Guidelines for transfusion of platelets are de-
rived from consensus opinion and experience in patients
undergoing chemotherapy. Recommendations take into ac-
count the etiology of thrombocytopenia, platelet dysfunc-
tion, risk of bleeding, and presence of concomitant disor-
ders [129, 131].
II. Supportive Therapy of Severe Sepsis
A. Mechanical Ventilation of Sepsis-Induced Acute Lung
Injury (ALI)/Acute Respiratory Distress Syndrome
(ARDS).
1. We recommend that clinicians target a tidal volume
of 6 ml/kg (predicted) body weight in patients with
ALI/ARDS (Grade 1B).
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2. We recommend that plateau pressures be measured
in patients with ALI/ARDS and that the initial upper
limit goal for plateau pressures in a passively inflated
patient be ≤ 30 cm H2O. Chest wall compliance should
be considered in the assessment of plateau pressure
(Grade 1C).
Rationale. Over the past 10 yrs, several multi-center
randomized trials have been performed to evaluate the
effects of limiting inspiratory pressure through moder-
ation of tidal volume [135–139]. These studies showed
differing results that may have been caused by differ-
ences between airway pressures in the treatment and
control groups [135, 140]. The largest trial of a volume-
and pressure-limited strategy showed a 9% decrease
of all-cause mortality in patients with ALI or ARDS
ventilated with tidal volumes of 6 mL/kg of predicted
body weight (PBW), as opposed to 12 mL/kg, and aiming
for a plateau pressure ≤ 30 cm H2O [135]. The use of lung
protective strategies for patients with ALI is supported
by clinical trials and has been widely accepted, but the
precise choice of tidal volume for an individual patient
with ALI may require adjustment for such factors as the
plateau pressure achieved, the level of PEEP chosen,
the compliance of the thoracoabdominal compartment
and the vigor of the patient’s breathing effort. Some
clinicians believe it may be safe to ventilate with tidal
volumes higher than 6 ml/kg PBW as long as the plateau
pressure can be maintained ≤ 30 cm H2O [141, 142]. The
validity of this ceiling value will depend on breathing
effort, as those who are actively inspiring generate higher
trans-alveolar pressures for a given plateau pressure than
those who are passively inflated. Conversely, patients
with very stiff chest walls may require plateau pressures
higher than 30 cm H2O to meet vital clinical objectives.
One retrospective study suggested that tidal volumes
should be lowered even with plateau pressures that are
≤ 30 cm H2O [143]. An additional observational study
suggested that knowledge of the plateau pressures was
associated with lower plateau pressures; however in this
trial, plateau pressure was not independently associated
with mortality rates across a wide range of plateau
pressures that bracketed 30 cm H2O [144]. The largest
clinical trial employing a lung protective strategy coupled
limited pressure with limited tidal volumes to demonstrate
a mortality benefit [135].
High tidal volumes that are coupled with high plateau
pressures should be avoided in ALI/ARDS. Clinicians
should use as a starting point the objective of reducing
tidal volumes over 1–2 hrs from its initial value toward
the goal of a “low” tidal volume (≈ 6 mL per kilogram of
predicted body weight) achieved in conjunction with an
end-inspiratory plateau pressure ≤ 30 cm H2O. If plateau
pressure remains > 30 after reduction of tidal volume to
6 ml/kg/PBW, tidal volume should be reduced further to
as low as 4 ml/kg/PBW (see Appendix E for ARDSnet
ventilator management and formula to calculate predicted
body weight).
No single mode of ventilation (pressure control, vol-
ume control, airway pressure release ventilation, high fre-
quency ventilation, etc.) has been consistently shown ad-
vantageous when compared with any other that respects
the same principles of lung protection.
3. We recommend that hypercapnia (allowing PaCO2
to increase above its pre-morbid baseline, so-called
permissive hypercapnia) be allowed in patients with
ALI/ARDS if needed to minimize plateau pressures
and tidal volumes (Grade 1C).
Rationale. An acutely elevated PaCO2 may have phys-
iologic consequences that include vasodilation as well
as an increased heart rate, blood pressure, and cardiac
output. Allowing modest hypercapnia in conjunction
with limiting tidal volume and minute ventilation has
been demonstrated to be safe in small, nonrandomized
series [145, 146]. Patients treated in larger trials that have
the goal of limiting tidal volumes and airway pressures
have demonstrated improved outcomes, but permissive
hypercapnia was not a primary treatment goal in these
studies [135]. The use of hypercapnia is limited in patients
with preexisting metabolic acidosis and is contraindicated
in patients with increased intracranial pressure. Sodium
bicarbonate or tromethamine (THAM®) infusion may
be considered in selected patients to facilitate use of
permissive hypercarbia [147, 148].
4. We recommend that positive end-expiratory pressure
(PEEP) be set so as to avoid extensive lung collapse at
end-expiration (Grade 1C).
Rationale. Raising PEEP in ALI/ARDS keeps lung
units open to participate in gas exchange. This will
increase PaO2 when PEEP is applied through either an
endotracheal tube or a face mask [149–151]. In ani-
mal experiments, avoidance of end-expiratory alveolar
collapse helps minimize ventilator induced lung injury
(VILI) when relatively high plateau pressures are in use.
One large multi-center trial of the protocol-driven use of
higher PEEP in conjunction with low tidal volumes did
not show benefit or harm when compared to lower PEEP
levels [152]. Neither the control nor experimental group
in that study, however, was clearly exposed to hazardous
plateau pressures. A recent multi-center Spanish trial com-
pared a high PEEP, low-moderate tidal volume approach
to one that used conventional tidal volumes and the least
PEEP achieving adequate oxygenation. A marked survival
advantage favored the former approach in high acuity
patients with ARDS [153]. Two options are recommended
for PEEP titration. One option is to titrate PEEP (and tidal
volume) according to bedside measurements of thora-
copulmonary compliance with the objective of obtaining
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the best compliance, reflecting a favorable balance of lung
recruitment and overdistention [154]. The second option
is to titrate PEEP based on severity of oxygenation deficit
and guided by the FIO2 required to maintain adequate
oxygenation [135] (see Appendix D.). Whichever the
indicator-compliance or oxygenation-recruiting maneu-
vers are reasonable to employ in the process of PEEP
selection. Blood pressure and oxygenation should be
monitored and recruitment discontinued if deterioration
in these parameters is observed. A PEEP > 5 cm H2O is
usually required to avoid lung collapse [155].
5. We suggest prone positioning in ARDS patients requir-
ing potentially injurious levels of FIO2 or plateau pres-
sure who are not at high risk for adverse consequences
of positional changes in those facilities who have expe-
rience with such practices (Grade 2C).
Rationale. Several smaller studies and one larger study
have shown that a majority of patients with ALI/ARDS
respond to the prone position with improved oxygena-
tion [156–159]. One large multi-center trial of prone
positioning for approximately 7 hrs/day did not show im-
provement in mortality rates in patients with ALI/ARDS;
however, a post hoc analysis suggested improvement
in those patients with the most severe hypoxemia by
PaO2/FIO2 ratio, in those exposed to high tidal volumes,
and those who improved CO2 exchange as a result of
proning [159]. A second large trial of prone positioning,
conducted for an average of approximately 8 hours per
day for 4 days in adults with hypoxemic respiratory
failure of low-moderate acuity, confirmed improvement
in oxygenation but also failed to show a survival advan-
tage [160]. However, a randomized study that extended the
length of time for proning each day to a mean of 17 hours
for a mean of 10 days supported benefit of proning,
with randomization to supine position an independent
risk factor for mortality by multivariate analysis [161].
Prone positioning may be associated with potentially
life-threatening complications, including accidental dis-
lodgment of the endotracheal tube and central venous
catheters, but these complications can usually be avoided
with proper precautions.
6. A) Unless contraindicated, we recommend mechani-
cally ventilated patients be maintained with the head
of the bed elevated to limit aspiration risk and to pre-
vent the development of ventilator-associated pneumo-
nia (Grade 1B).
B) We suggest that the head of bed is elevated approx-
imately 30–45 degrees (Grade 2C).
Rationale. The semirecumbent position has been demon-
strated to decrease the incidence of ventilator-associated
pneumonia (VAP) [164]. Enteral feeding increased the risk
of developing VAP; 50% of the patients who were fed en-
terally in the supine position developing VAP [162]. How-
ever, the bed position was only monitored once a day, and
patients who did not achieve the desired bed elevation were
not included in the analysis [162]. A recent study did not
show a difference in in incidence of VAP between patients
maintained in supine and semirecumbent positions [163].
In this study, patients in the semirecumbent position did
not consistently achieve the desired head of the bed eleva-
tion, and the head of bed elevation in the supine group ap-
proached that of the semirecumbent group by day 7 [163].
When necessary, patients may be laid flat for procedures,
hemodynamic measurements, and during episodes of hy-
potension. Patients should not be fed enterally with the
head of the bed at 0°.
7. We suggest that noninvasive mask ventilation (NIV)
only be considered in that minority of ALI/ARDS pa-
tients with mild-moderate hypoxemic respiratory fail-
ure (responsive to relatively low levels of pressure sup-
port and PEEP) with stable hemodynamics who can be
made comfortable and easily arousable, who are able
to protect the airway, spontaneously clear the airway of
secretions, and are anticipated to recover rapidly from
the precipitating insult. A low threshold for airway in-
tubation should be maintained (Grade 2B).
Rationale. Obviating the need for airway intubation con-
fers multiple advantages: better communication, lower in-
cidence of infection, reduced requirements for sedation.
Two RCTs demonstrate improved outcome with the use
of NIV when it can be employed successfully [164, 165].
Unfortunately, only a small percentage of patients with life
threatening hypoxemia can be managed in this way.
8. We recommend that a weaning protocol be in place,
and mechanically ventilated patients with severe sep-
sis undergo spontaneous breathing trials on a regular
basis to evaluate the ability to discontinue mechani-
cal ventilation when they satisfy the following criteria:
a) arousable; b) hemodynamically stable (without va-
sopressor agents); c) no new potentially serious con-
ditions; d) low ventilatory and end-expiratory pressure
requirements; and e) FIO2 requirements that could be
safely delivered with a face mask or nasal cannula. If
the spontaneous breathing trial is successful, consider-
ation should be given for extubation (see Appendix E).
Spontaneous breathing trial options include a low level
of pressure support, continuous positive airway pres-
sure (≈ 5 cm H2O) or a T-piece (Grade 1A).
Rationale. Recent studies demonstrate that daily spont-
aneous breathing trials in appropriately selected patients
reduce the duration of mechanical ventilation [166–169].
Successful completion of spontaneous breathing trials
leads to a high likelihood of successful discontinuation of
mechanical ventilation.
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9. We recommend against the routine use of the pul-
monary artery catheter for patients with ALI/ARDS
(Grade 1A).
Rationale. While insertion of a pulmonary artery catheter
may provide useful information on a patient’s volume
status and cardiac function, potential benefits of such infor-
mation may be confounded by differences in interpretation
of results [170–172], lack of correlation of pulmonary
artery occlusion pressures with clinical response [173],
and absence of a proven strategy to use catheter results
to improve patient outcomes [174]. Two multi-center
randomized trials: one in patients with shock or acute
lung injury [175], and one in patients with acute lung
injury [176] failed to show benefit with the routine use
of pulmonary artery catheters in patients with acute lung
injury. In addition, other studies in different types of criti-
cally ill patients have failed to show definitive benefit with
routine use of the pulmonary artery catheter [177–179].
Well-selected patients remain appropriate candidates for
pulmonary artery catheter insertion when the answers to
important management decisions depend on information
only obtainable from direct measurements made within
the pulmonary artery.
10. To decrease days of mechanical ventilation and ICU
length of stay we recommend a conservative fluid
strategy for patients with established acute lung injury
who do not have evidence of tissue hypoperfusion
(Grade 1C).
Rationale. Mechanisms for the development of pulmonary
edema in patients with acute lung injury include increased
capillary permeability, increased hydrostatic pressure and
decreased oncotic pressure [180, 181]. Small prospective
studies in patients with critical illness and acute lung injury
have suggested that less weight gain is associated with im-
proved oxygenation [182] and fewer days of mechanical
ventilation [183, 184]. Use of a fluid conservative strat-
egy directed at minimizing fluid infusion and weight gain
in patients with acute lung injury based on either a cen-
tral venous catheter or a pulmonary artery catheter along
with clinical parameters to guide treatment strategies led
to fewer days of mechanical ventilation and reduced length
of ICU stay without altering the incidence of renal failure
or mortality rates [185]. Of note, this strategy was only
used in patients with established acute lung injury, some of
whom had shock present. Active attempts to reduce fluid
volume were conducted only during periods free of shock.
B. Sedation, Analgesia, and Neuromuscular Blockade
in Sepsis
1. We recommend sedation protocols with a sedation
goal when sedation of critically ill mechanically
ventilated patients with sepsis is required (Grade 1B).
Rationale. A growing body of evidence indicates that the
use of protocols for sedation of critically ill ventilated
patients can reduce the duration of mechanical venti-
lation and ICU and hospital length of stay [186–188].
A randomized, controlled clinical trial found that protocol
use resulted in reduced duration of mechanical ventila-
tion, reduced lengths of stay, and reduced tracheostomy
rates [186].
A report describing the implementation of protocols,
including sedation and analgesia, using a short-cycle
improvement methodology in the management of criti-
cally ill patients demonstrated a decrease in the cost per
patient day and a decrease of ICU length of stay [187].
Furthermore, a prospective before-and-after study on
the implementation of a sedation protocol demonstrated
enhanced quality of sedation with reduced drug costs. Al-
though this protocol also may have contributed to a longer
duration of mechanical ventilation, ICU discharge was
not delayed [188]. Despite the lack of evidence regarding
the use of subjective methods of evaluation of sedation in
septic patients, the use of a sedation goal has been shown
to decrease the duration of mechanical ventilation in criti-
cally ill patients [186]. Several subjective sedation scales
have been described in the medical literature. Currently,
however, there is not a clearly superior sedation evaluation
methodology against which these sedation scales can be
evaluated [189]. The benefits of sedation protocols appear
to outweigh the risks.
2. We recommend intermittent bolus sedation or
continuous infusion sedation to predetermined end
points (e. g., sedation scales) with daily interrup-
tion/lightening of continuous infusion sedation with
awakening and retitration if necessary for sedation ad-
ministration to septic mechanically ventilated patients
(Grade 1B).
Rationale. Although not specifically studied in patients
with sepsis, the administration of intermittent sedation,
daily interruption, and retitration or systemic titration to
a predefined end point have been demonstrated to decrease
the duration of mechanical ventilation [186, 189, 190]. Pa-
tients receiving neuromuscular blocking agents (NMBAs)
must be individually assessed regarding discontinuation
of sedative drugs because neuromuscular blocking drugs
must also be discontinued in that situation. The use of
intermittent vs. continuous methods for the delivery of
sedation in critically ill patients has been examined. An
observational study of mechanically-ventilated patients
showed that patients receiving continuous sedation had
significantly longer durations of mechanical ventilation
and ICU and hospital length of stay [191].
Similarly, a prospective, controlled study in 128
mechanically-ventilated adults receiving continuous intra-
venous sedation demonstrated that a daily interruption in
the “continuous” sedative infusion until the patient was
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awake decreased the duration of mechanical ventilation
and ICU length of stay [192]. Although the patients did
receive continuous sedative infusions in this study, the
daily interruption and awakening allowed for titration
of sedation, in effect, making the dosing intermittent.
Systematic (protocolized) titration to a predefined end
point has also been shown to alter outcome [186]. Addi-
tionally, a randomized prospective blinded observational
study demonstrated that although myocardial ischemia is
common in critically ill ventilated patients, daily sedative
interruption is not associated with an increased occurrence
of myocardial ischemia [193]. Thus, the benefits of daily
interruption of sedation appear to outweigh the risks.
These benefits include potentially shorter duration of
mechanical ventilation and ICU stay, better assessment of
neurologic function, and reduced costs.
3. We recommend that NMBAs be avoided if possible in
the septic patient due to the risk of prolonged neuro-
muscular blockade following discontinuation. If NM-
BAs must be maintained, either intermittent bolus as
required or continuous infusion with monitoring the
depth of blockade with train-of-four monitoring should
be used (Grade 1B).
Rationale. Although NMBAs are often administered
to critically ill patients, their role in the ICU setting is
not well defined. No evidence exists that maintaining
neuromuscular blockade in this patient population reduces
mortality or major morbidity. In addition, no studies have
been published that specifically address the use of NMBAs
in septic patients.
The most common indication for NMBA use in
the ICU is to facilitate mechanical ventilation [194].
When appropriately utilized, NMBAs may improve
chest wall compliance, prevent respiratory dyssyn-
chrony, and reduce peak airway pressures [195]. Mus-
cle paralysis may also reduce oxygen consumption
by decreasing the work of breathing and respiratory
muscle blood flow [196]. However, a randomized,
placebo-controlled clinical trial in patients with se-
vere sepsis demonstrated that oxygen delivery, oxy-
gen consumption, and gastric intramucosal pH were
not improved during profound neuromuscular block-
ade [197].
An association between NMBA use and myopathies
and neuropathies has been suggested by case studies
and prospective observational studies in the critical
care population [195, 198–201]. The mechanisms by
which NMBA’s produced or contribute to myopathies
and neuropathies in critically ill patients are presently
unknown. There appears to be an added association with
the concurrent use o NMBA’s and steroids. Although
no specific studies exist specific to the septic patient
population, it seems clinically prudent based on existent
knowledge that NMBA’s not be administered unless there
is a clear indication for neuromuscular blockade that
can not be safely achieved with appropriate sedation and
analgesia” [195].
Only one prospective, randomized clinical trial has
evaluated peripheral nerve stimulation vs. standard clinical
assessment in ICU patients. Rudis et al. [202] randomized
77 critically ill patients requiring neuromuscular blockade
in the ICU to receive dosing of vecuronium based on
train-of-four stimulation or clinical assessment (control).
The peripheral nerve stimulation group received less drug
and recovered neuromuscular function and spontaneous
ventilation faster than the control group. Nonrandomized
observational studies have suggested that peripheral nerve
monitoring reduces or has no effect on clinical recovery
from NMBAs in the ICU setting [203, 204].
Benefits to neuromuscular monitoring, including faster
recovery of neuromuscular function and, shorter intubation
times, appear to exist. A potential for cost savings (reduced
total dose of NMBAs and shorter intubation times) also
may exist, although this has not been studied formally.
C. Glucose Control
1. We recommend that, following initial stabilization, pa-
tients with severe sepsis and hyperglycemia who are
admitted to the ICU receive IV insulin therapy to re-
duce blood glucose levels (Grade 1B).
2. We suggest use of a validated protocol for insulin
dose adjustments and targeting glucose levels to the
< 150 mg/dl range (Grade 2C).
3. We recommend that all patients receiving intravenous
insulin receive a glucose calorie source and that blood
glucose values be monitored every 1–2 hours until glu-
cose values and insulin infusion rates are stable and
then every 4 hours thereafter (Grade 1C).
4. We recommend that low glucose levels obtained with
point-of-care testing of capillary blood be interpreted
with caution, as such measurements may overestimate
arterial blood or plasma glucose values (Grade 1B).
Rationale. The consensus on glucose control in severe
sepsis was achieved at the first committee meeting and
subsequently approved by the entire committee (see
Appendix G for committee vote). One large randomized
single center trial in a predominantly cardiac surgical
ICU demonstrated a reduction in ICU mortality with
intensive IV insulin (Leuven Protocol) targeting blood
glucose to 80–110 mg/dl (for all patients relative 43%,
and absolute 3.4% mortality reduction, and for those with
> 5 day ICU length of stays (LOS) a 48% relative and
9.6% absolute mortality reduction) [205]. A reduction in
organ dysfunction and ICU LOS (from a median of 15
to12 days) was also observed in the subset with ICU LOS
> 5 days. A second randomized trial of intensive insulin
therapy using the Leuven Protocol enrolled medical ICU
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patients with an anticipated ICU LOS of > 3 days in
three MICUs [206]. Overall, mortality was not reduced
but ICU and hospital LOS were reduced associated with
earlier weaning from mechanical ventilation and less
acute kidney injury. In patients with a medical ICU LOS
> 3 days, hospital mortality was reduced with intensive
insulin therapy (43% versus 52.5%; p = 0.009). However,
investigators were unsuccessful in predicting ICU LOS
and 433 patients (36%) had an ICU LOS of < 3 days.
Furthermore, use of the Leuven Protocol in the medical
ICU resulted in a nearly three-fold higher rate of hypo-
glycemia than in the original experience (18% versus
6.2% of patients) [205, 206].
One large before-and-after observational trial showed
a 29% relative and 6.1% absolute reduction in mortality
and a 10.8% reduction in median ICU LOS [207]. In a sub-
group of 53 patients with septic shock there was an abso-
lute mortality reduction of 27% and a relative reduction of
45% (p = 0.02). Two additional observational studies re-
port an association of mean glucose levels with reductions
in mortality, polyneuropathy, acute renal failure, nosoco-
mial bacteremia, and number of transfusions, and suggest
a glucose threshold for improved mortality lies somewhere
between 145 and 180 mg/dl [208, 209]. However, a large
observational study (n = 7,049) suggested that both a lower
mean glucose and less variation of blood glucose may be
important [210]. A meta-analysis of 35 trials on insulin
therapy in critically ill patients, including 12 randomized
trials, demonstrated a 15% reduction in short term mor-
tality (RR 0.85, 95% confidence interval 0.75–0.97) but
did not include any studies of insulin therapy in medical
ICUs [211].
Two additional multicenter RCTs of intensive insulin
therapy, one focusing on patients with severe sepsis
(VISEP) and the second on medical and surgical ICU
patients, failed to demonstrate improvement in mortality,
but are not yet published [212, 213]. Both stopped earlier
than planned because of high rates of hypoglycemia and
adverse events in the intensive insulin groups. A large
RCT that is planned to compare targeting 80–110 mg/dl
(4.5–6.0 mmol/L) versus 140–180 mg/dl (8–10 mmol/L)
and recruit more than 6,000 patients (Normoglycemia in
Intensive Care Evaluation and Survival Using Glucose Al-
gorithm Regulation, or NICE-SUGAR) is ongoing [214].
Several factors may affect the accuracy and repro-
ducibility of point-of-care testing of blood capillary blood
glucose, including the type and model of the device used,
user expertise, and patient factors including hematocrit
(false elevation with anemia), PaO2, and drugs [215]. One
report showed overestimation of arterial plasma glucose
values by capillary point-of-care testing sufficient to result
in different protocol-specified insulin dose titration. The
disagreement between protocol-recommended insulin
doses was largest when glucose values were low [216].
A recent review of 12 published insulin infusion protocols
for critically ill patients showed wide variability in insulin
dose recommendations and variable glucose control dur-
ing simulation [217]. This lack of consensus about optimal
dosing of IV insulin may reflect variability in patient
factors (severity of illness, surgical vs. medical settings,
etc) or practice patterns (e. g., approaches to feeding,
IV dextrose) in the environments in which these protocols
were developed and tested. Alternatively, some protocols
may be more effective than other protocols. This conclu-
sion is supported by the wide variability in hypoglycemia
rates reported with protocols [205–207, 212, 213]. Thus,
the use of a validated and safe intensive insulin protocol
is important not only for clinical care but also for the
conduct of clinical trials to avoid hypoglycemia, adverse
events, and premature termination of these trials before
the efficacy signal, if any, can be determined.
The finding of reduced morbidity and mortality within
the longer ICU length of stay subsets along with accept-
able cost weighed heavily on our recommendation to at-
tempt glucose control after initial stabilization of the pa-
tient with hyperglycemia and severe sepsis. However, the
mortality benefit and safety of intensive insulin therapy
(goal to normalize blood glucose) has been questioned by
2 recent trials and we recommend maintaining glucose lev-
els < 150 mg/dl until recent and ongoing trials are pub-
lished or completed. Further study of protocols that have
been validated to be safe and effective for controlling blood
glucose concentrations and blood glucose variation in the
severe sepsis population are needed.
D. Renal Replacement
1. We suggest that continuous renal replacement ther-
apies and intermittent hemodialysis are equivalent
in patients with severe sepsis and acute renal failure
(Grade 2B).
2. We suggest the use of continuous therapies to facili-
tate management of fluid balance in hemodynamically
unstable septic patients (Grade 2D).
Rationale. Although numerous nonrandomized studies
have reported a nonsignificant trend toward improved
survival using continuous methods [218–225], 2 meta-
analyses [226, 227] report the absence of significant dif-
ference in hospital mortality between patients who receive
continuous and intermittent renal replacement therapies.
This absence of apparent benefit of one modality over the
other persists even when the analysis is restricted to only
randomized studies [227]. To date, 5 prospective random-
ized studies have been published [228–232]. Four of them
found no significant difference in mortality [229–232].
One study found significantly higher mortality in the
continuous treatment group [228], but imbalanced ran-
domization had led to a higher baseline severity of illness
in this group. When a multivariable model was used to
adjust for severity of illness, no difference in mortality was
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apparent between the groups [228]. It is important to note
that most studies comparing modes of renal replacement
in the critically ill have included a small number of pa-
tients and some major weaknesses (randomization failure,
modifications of therapeutic protocol during the study
period, combination of different types of continuous renal
replacement therapies, small number of heterogenous
groups of patients enrolled). The most recent and largest
randomized study [232] enrolled 360 patients and found
no significant difference in survival between the 2 groups.
Moreover, there is no current evidence to support the use
of continuous therapies in sepsis independent of renal
replacement needs.
Concerning the hemodynamic tolerance of each
method, no current evidence exists to support a better
tolerance with continuous treatments. Only 2 prospective
studies [230, 233] have reported a better hemodynamic
tolerance with continuous treatment, with no improvement
in regional perfusion [233] and no survival benefit [230].
Four other prospective studies did not find any significant
difference in mean arterial pressure or drop in systolic
pressure between the 2 methods [229, 231, 232, 234].
Concerning fluid balance management, 2 studies report
a significant improvement in goal achievement with con-
tinuous methods [228, 230]. In summary, current evidence
is insufficient to draw strong conclusions regarding the
mode of replacement therapy for acute renal failure in
septic patients.
Four randomized, controlled trials have addressed
whether the dose of continuous renal replacement affects
outcomes in patients with acute renal failure [235–238].
Three found improved mortality in patients receiving
higher doses of renal replacement [235, 237, 238], while
one [236] did not. None of these trials was conducted
specifically in patients with sepsis. Although the weight
of current evidence suggests that higher doses of renal
replacement may be associated with improved outcomes,
these results may not be easily generalizable. The results
of 2 very large multicenter randomized trials comparing
the dose of renal replacement (ATN in the United States
and RENAL in Australia and New Zealand) will be
available in 2008 and will greatly inform practice.
E. Bicarbonate Therapy
1. We recommend against the use of sodium bicarbonate
therapy for the purpose of improving hemodynamics
or reducing vasopressor requirements in patients with
hypoperfusion-induced lactic acidemia with pH ≥ 7.15
(Grade 1B).
Rationale. No evidence supports the use of bicarbonate
therapy in the treatment of hypoperfusion-induced lac-
tic acidemia associated with sepsis. Two randomized,
blinded, crossover studies that compared equimolar saline
and bicarbonate in patients with lactic acidosis failed to
reveal any difference in hemodynamic variables or vaso-
pressor requirements. [239, 240] The number of patients
with pH < 7.15 in these studies was small. Bicarbonate
administration has been associated with sodium and fluid
overload, an increase in lactate and pCO2, and a decrease
in serum ionized calcium; but the relevance of these
parameters to outcome is uncertain. The effect of bicar-
bonate administration on hemodynamics and vasopressor
requirements at lower pH as well as the effect on clinical
outcomes at any pH is unknown. No studies have examined
the effect of bicarbonate administration on outcomes.
F. Deep Vein Thrombosis Prophylaxis
1. We recommend that severe sepsis patients receive
deep vein thrombosis (DVT) prophylaxis with either
(a) low-dose unfractionated heparin (UFH) adminis-
tered b.i.d. or t.i.d. or (b) daily low-molecular weight
heparin (LMWH) unless there are contraindications
(i. e., thrombocytopenia, severe coagulopathy, active
bleeding, recent intracerebral hemorrhage) (Grade 1A).
2. We recommend that septic patients who have a con-
traindication for heparin use receive mechanical pro-
phylactic device such as graduated compression stock-
ings (GCS) or intermittent compression devices (ICD)
unless contraindicated (Grade 1A).
3. We suggest that in very high-risk patients such as those
who have severe sepsis and history of DVT, trauma,
or orthopedic surgery, a combination of pharmacologic
and mechanical therapy be used unless contraindicated
or not practical (Grade 2C).
4. We suggest that in patients at very high risk, LMWH
be used rather than UFH as LMWH is proven superior
in other high-risk patients (Grade 2C).
Rationale. ICU patients are at risk for DVT [241]. Signifi-
cant evidence exists for benefit of DVT prophylaxis in ICU
patients in general. No reasons suggest that severe sepsis
patients would be different from the general patient popu-
lation.
Nine randomized placebo controlled clinical trials of
DVT prophylaxis in general populations of acutely ill pa-
tients exist [242–250]. All 9 trials showed reduction in
DVT or PE. The prevalence of infection/sepsis was 17%
in all studies in which this was ascertainable, with a 52%
prevalence of infection/sepsis patients in the study that in-
cluded ICU patients only. Benefit of DVT prophylaxis is
also supported by meta-analyses [251, 252]. With that in
mind, DVT prophylaxis would appear to have a high grade
for quality of evidence (A). As the risk of administration
to the patient is small, the gravity of the potential result of
not administering is great, and the cost is low, the grading
of the strength of the recommendation is strong. The evi-
dence supports equivalency of LMWH and UFH in gen-
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eral medical populations. A recent meta-analysis compar-
ing b.i.d. and t.i.d. UFH demonstrated that t.i.d. UFH pro-
duced better efficacy and b.i.d. less bleeding [253]. Practi-
tioners should use underlying risk for VTE and bleeding to
individualize choice of b.i.d. versus t.i.d.
The cost of LMWH is greater and the frequency of in-
jection is less. UFH is preferred over LMWH in patients
with moderate to severe renal dysfunction.
Mechanical methods (ICD and GCS) are recom-
mended when anticoagulation is contraindicated or as
an adjunct to anticoagulation in the very high-risk pa-
tients [254–256]. In very high-risk patients, LMWH is
preferred over UFH [257–259]. Patients receiving heparin
should be monitored for development of heparin-induced
thrombocytopenia (HIT).
G. Stress Ulcer Prophylaxis (SUP)
We recommend that stress ulcer prophylaxis using H2
blocker (Grade 1A) or proton pump inhibitor PPI (Grade
1B) be given to patients with severe sepsis to prevent upper
GI bleed. Benefit of prevention of upper GI bleed must be
weighed against potential effect of an increased stomach
pH on development of ventilator-associated pneumonia.
Rationale. Although no study has been performed
specifically in patients with severe sepsis, trials confirming
the benefit of stress ulcer prophylaxis reducing upper GI
bleeds in general ICU populations would suggest that
20–25% of patients enrolled in these types of trials have
sepsis [260–263]. This benefit should be applicable to pa-
tients with severe sepsis and septic shock. In addition, the
conditions shown to benefit from stress ulcer prophylaxis
(coagulopathy, mechanical ventilation, hypotension) are
frequently present in patients with severe sepsis and septic
shock [264, 265].
Although there are individual trials that have not
shown benefit from SUP, numerous trials and a meta-
analysis show reduction in clinically significant upper
GI bleeding, which we consider significant even in the
absence of proven mortality benefit [266–269]. The benefit
of prevention of upper GI bleed must be weighed against
the potential effect of increased stomach pH on greater
incidence of ventilator-associated pneumonia [270]. Those
severe sepsis patients with the greatest risk of upper GI
bleeding are likely to benefit most from stress ulcer pro-
phylaxis. The rationale for the preference for suppression
of acid production over sulcrafate was based on the study
of 1200 patients by Cook et al comparing H2 blockers
and sucralfate and a meta-analysis [271, 272]. 2 studies
support equivalency between H2 blockers and PPIs. One
was in very ill ICU patients. The second study is larger and
demonstrates non-inferiority of omeprazole suspension
for clinically significant stress ulcer bleeding [273, 274].
No data relating to utility of enteral feeding in stress
ulcer prophylaxis exist. Patients should be periodically
evaluated for continued need for prophylaxis.
H. Selective Digestive Tract Decontamination (SDD)
The guidelines group was evenly split on the issue of SDD,
with equal numbers weakly in favor and against recom-
mending the use of SDD (see appendix H). The committee
therefore chose not to make a recommendation for the use
of SDD specifically in severe sepsis at this time. The final
consensus on use of SDD in severe sepsis was achieved at
the last nominal committee meeting and subsequently ap-
proved by the entire committee (see Appendix H for com-
mittee vote).
Rationale. The cumulative conclusion from the liter-
ature demonstrates that prophylactic use of SDD (enteral
non-absorbable antimicrobials and short-course intra-
venous antibiotics) reduces infections, mainly pneumonia,
and mortality in the general population of critically
ill and trauma patients [275–286] without promoting
emergence of resistant Gram negative bacteria. Post hoc
subgroup analyses [287, 288] of two prospective blinded
studies [289, 290] suggest that SDD reduces nosocomial
(secondary) infections in ICU patients admitted with
primary infections [268] and may reduce mortality [288].
No studies of SDD specifically focused on patients with
severe sepsis or septic shock. The use of SDD in severe
sepsis patients would be targeted toward preventing
secondary infection. As the main effect of SDD is in pre-
venting ventilator-associated pneumonia (VAP), studies
comparing SDD with non-antimicrobial interventions
such as ventilator bundles for reducing VAP are needed.
Further investigation is required to determine the com-
parative efficacy of these two interventions, separately or
in combination. Although studies incorporating enteral
vancomycin in the regimen appear to be safe [291, 292,
293] concerns persist about the potential for emergence of
resistant Gram positive infections.
I. Consideration for Limitation of Support
We recommend that advance care planning, including the
communication of likely outcomes and realistic goals of
treatment, be discussed with patients and families (Grade
1D).
Rationale. Decisions for less aggressive support
or withdrawal of support may be in the patient’s best
interest. [294–296] Too frequently, inadequate physi-
cian/family communication characterizes end-of-life care
in the ICU. The level of life support given to ICU patients
may not be consistent with their wishes. Early and frequent
caregiver discussions with patients who face death in the
ICU and with their loved ones may facilitate appropriate
application and withdrawal of life-sustaining therapies.
A recent RCT demonstrated reduction of anxiety and
depression in family members when end-of-life meetings
were carefully planned, conducted, included advance
care planning, and provided relevant information about
diagnosis, prognosis, and treatment [297].
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III. Pediatric Considerations in Severe Sepsis
While sepsis in children is a major cause of mortality, the
overall mortality from severe sepsis in children is much
lower that that in adults, estimated at about 10% [298].
The definitions for severe sepsis and septic shock in
children are similar but not identical to the definitions in
adults [299]. In addition to age-appropriate differences
in vital signs, the definition of systemic inflammatory
response syndrome requires the presence of either tem-
perature or leukocyte abnormalities. The presence of
severe sepsis requires sepsis plus cardiovascular dys-
function or ARDS or 2 or more other organ dysfunc-
tions [299].
A. Antibiotics
1. We recommend antibiotics be administered within one
hour of the identification of severe sepsis, after appro-
priate cultures have been obtained (Grade 1D).
Early antibiotic therapy is as critical for children with se-
vere sepsis as it is for adults.
B. Mechanical Ventilation
No graded recommendations.
Due to low functional residual capacity, young infants
and neonates with severe sepsis may require early intuba-
tion [300]. Drugs used for intubation have important side
effects in these patients, for example, concerns have been
raised about the safety of using etomidate in children with
meningococcal sepsis because of adrenal suppression ef-
fect [301]. The principles of lung-protective strategies are
applied to children as they are to adults.
C. Fluid Resuscitation
1. We suggest initial resuscitation begin with in-
fusion of crystalloids with boluses of 20 mL/kg
over 5–10 minutes, titrated to clinical monitors
of cardiac output, including heart rate, urine out-
put, capillary refill, and level of consciousness
(Grade 2C).
Intravenous access for fluid resuscitation and in-
otrope/vasopressor infusion is more difficult to attain
in children than in adults. The American Heart Associ-
ation along with the American Academy of Pediatrics
has developed pediatric advanced life support guidelines
for emergency establishment of intravascular support
encouraging early intraosseous access [302]. On the basis
of a number of studies, it is accepted that aggressive
fluid resuscitation with crystalloids or colloids is of
fundamental importance to survival of septic shock in
children [303–308]. Three randomized, controlled trials
compare the use of colloid to crystalloid resuscitation in
children with dengue shock [303, 307, 308]. No difference
in mortality between colloid or crystalloid resuscitation
was shown.
Children normally have a lower blood pressure than
adults, and fall in blood pressure can be prevented by
vasoconstriction and increasing heart rate. Therefore,
blood pressure by itself is not a reliable end point for
assessing the adequacy of resuscitation. However, once
hypotension occurs, cardiovascular collapse may soon
follow. Hepatomegaly occurs in children who are fluid
overloaded and can be a helpful sign of adequacy of fluid
resuscitation. Large fluid deficits typically exist and initial
volume resuscitation usually requires 40–60 mL/kg but
can be much higher [304–308]. However, the rate of fluid
administration should be reduced substantially when there
are (clinical) signs of adequate cardiac filling without
hemodynamic improvement.
D. Vasopressors/Inotropes (should be used in volume
loaded patients with fluid refractory shock)
1. We suggest dopamine as the first choice of support
for the pediatric patient with hypotension refractory to
fluid resuscitation (Grade 2C).
In the initial resuscitation phase, vasopressor therapy may
be required to sustain perfusion pressure, even when hy-
povolemia has not yet been resolved. Children with severe
sepsis can present with low cardiac output and high sys-
temic vascular resistance, high cardiac output and low sys-
temic vascular resistance, or low cardiac output and low
systemic vascular resistance shock. At various stages of
sepsis or the treatment thereof, a child may move from
one hemodynamic state to another. Vasopressor or inotrope
therapy should be used according to the clinical state of the
child.
Dopamine-refractory shock may reverse with
epinephrine or norepinephrine infusion [309].
2. We suggest that patients with low cardiac output
and elevated systemic vascular resistance states (cool
extremities, prolonged capillary refill, decreased urine
output but normal blood pressure following fluid
resuscitation) be given dobutamine (Grade 2C).
The choice of vasoactive agent is determined by the clin-
ical examination. For the child with a persistent low car-
diac output state with high systemic vascular resistance
despite fluid resuscitation and inotropic support, vasodila-
tor therapy may reverse shock [310]. When pediatric pa-
tients remain in a normotensive low cardiac output and
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high vascular resistance state despite epinephrine and va-
sodilator therapy, the use of a phosphodiesterase inhibitor
may be considered [311–313]. In the case of extremely
low systemic vascular resistance despite the use of nore-
pinephrine, vasopressin use has been described in a num-
ber of case-reports. Thus far there is no clear evidence for
the use of vasopressin in pediatric sepsis [314, 315].
E. Therapeutic End Points
1. We suggest that the therapeutic end points of re-
suscitation of septic shock be normalization of
the heart rate, capillary refill of < 2 secs, nor-
mal pulses with no differential between peripheral
and central pulses, warm extremities, urine output
> 1mL.kg –1.hr–1, and normal mental status [290]
(Grade 2C).
Capillary refill may be less reliable in a cold environment.
Other end points that have been widely used in adults and
may logically apply to children include decreased lactate
and improved base deficit, ScvO2 ≥ 70% or SvO2 ≥ 65%,
CVP of 8–12 mm Hg or other methods to analyze cardiac
filling. Optimizing preload optimizes cardiac index. When
using measurements to assist in identifying acceptable car-
diac output in children with systemic arterial hypoxemia
such as cyanotic congenital heart disease or severe pul-
monary disease, arterial-venous oxygen content difference
is a better marker than mixed venous hemoglobin satura-
tion with oxygen. As noted previously, blood pressure by
itself is not a reliable end point for resuscitation. If a ther-
modilution catheter is used, therapeutic end points are car-
diac index > 3.3 and < 6.0 L.min–1.m–2 with normal coro-
nary perfusion pressure (mean arterial pressure – central
venous pressure) for age. [290] Using clinical endpoints
such as reversal of hypotension and restoration of capil-
lary refill for initial resuscitation at the community hospi-
tal level before transfer to a tertiary center was associated
with significantly improved survival rates in children with
septic shock [305]. Development of a transport system in-
cluding publicizing to local hospitals and transport with
mobile intensive care services significantly decreased the
case fatality rate from meningococcal disease in the United
Kingdom [316].
F. Approach to Pediatric Septic Shock
Figure 1 shows a flow diagram summarizing an approach
to pediatric septic shock [317].
G. Steroids
1. We suggest that hydrocortisone therapy be reserved for
use in children with catecholamine resistance and sus-
pected or proven adrenal insufficiency (Grade 2C).
Patients at risk for adrenal insufficiency include children
with severe septic shock and purpura [318, 319], children
who have previously received steroid therapies for chronic
illness, and children with pituitary or adrenal abnormali-
ties. Children who have clear risk factors for adrenal insuf-
ficiency should be treated with stress dose steroids (hydro-
cortisone 50 mg/m2/24hr).
Adrenal insufficiency in pediatric severe sepsis is
associated with a poor prognosis [320]. No strict def-
initions exist, but absolute adrenal insufficiency in the
case of catecholamine-resistant septic shock is assumed
at a random total cortisol concentration < 18 µg/dL
(496 nmol/L). A post 30- or 60-min ACTH stimulation
test increase in cortisol of ≤ 9 µg/dL (248 mmol/L) has
been used to define relative adrenal insufficiency. The
treatment of relative adrenal insufficiency in children
with septic shock is controversial. A retrospective study
from a large administrative database recently reported
that the use of any corticosteroids in children with severe
sepsis was associated with increased mortality (OR 1.9
95% CI 1.7–2.2) [321]. While steroids may have been
given preferentially to more severely ill children, the
use of steroids was an independent predictor of mor-
tality in multivariable analysis [321]. Given the lack
of data in children and potential risk, steroids should
not be used in those children who do not meet minimal
criteria for adrenal insufficiency. A randomized, con-
trolled trial in children with septic shock is very much
needed.
H. Protein C and Activated Protein C
1. We recommend against the use rhAPC in children
(Grade 1B).
Protein C concentrations in children reach adult values
at the age of 3 yrs. This might indicate that the impor-
tance of protein C supplementation either as protein
C concentrate or as rhAPC is even greater in young
children than in adults [322]. There has been one dose
finding, randomized, placebo-controlled study performed
using protein C concentrate. This study was not pow-
ered to show an effect on mortality rate, but did show
a positive effect on sepsis-induced coagulation distur-
bances [323]. An RCT of rhAPC in pediatric severe
sepsis patients was stopped by recommendation of the
Data Monitoring Committee for futility after enrol-
lment of 399 patients. 28-day all cause mortality: 18%
placebo group vs. 17% APC group. Major amputa-
tions occurred in 3% of the placebo group vs. 2% in
the APC group [324]. Due to the increased risk of
bleeding (7% vs. 6% in the pediatric trial) and lack of
proof of efficacy, rhAPC is not recommended for use in
children.
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Fig. 1 Approach to Pediatric
Shock
I. DVT Prophylaxis
1. We suggest the use of DVT prophylaxis in post-
pubertal children with severe sepsis (Grade 2C).
Most DVTs in young children are associated with
central venous catheters. Femoral venous catheters are
commonly used in children, and central venous catheter-
associated DVTs occur in approximately 25% of children
with a femoral central venous catheter. Heparin-bonded
catheters may decrease the risk of catheter-associated
DVT and should be considered for use in children with
severe sepsis. [325, 326] No data on the efficacy of unfrac-
tionated or low-molecular weight heparin prophylaxis to
prevent catheter-related DVT in children in the ICU exist.
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J. Stress Ulcer Prophylaxis
No graded recommendations.
Studies have shown that the rate of clinically important
gastrointestinal bleeding in children occurs at rates sim-
ilar to adults [327, 328]. As in adults, coagulopathy and
mechanical ventilation are risk factors for clinically im-
portant gastrointestinal bleeding. Stress ulcer prophylaxis
strategy is commonly used in mechanically-ventilated chil-
dren, usually with H2 blockers. Its effect is not known.
K. Renal Replacement Therapy
No graded recommendations.
Continuous veno-venous hemofiltration (CVVH)
may be clinically useful in children with anuria/severe
oliguria and fluid overload, but no large RCTs have
been performed comparing CVVH with intermittent dia-
lysis. A retrospective study of 113 critically ill children
reported that children with less fluid overload before
CVVH had better survival, especially in those children
with dysfunction of 3 or more organs [329]. CVVH or
other renal replacement therapy should be instituted in
children with anuria/severe oliguria before significant
fluid overload occurs.
L. Glycemic Control
No graded recommendations.
In general, infants are at risk for developing hypo-
glycemia when they depend on intravenous fluids. This
means that a glucose intake of 4–6 mg.kg–1.min–1 or
maintenance fluid intake with glucose 10%/NaCl contain-
ing solution is advised. Associations have been reported
between hyperglycemia and an increased risk of death
and longer length of stay [330]. A recent retrospective
PICU study reported associations of hyperglycemia,
hypoglycemia, and glucose variability with length of
stay and mortality rates. [331] No studies in pediatric
patients (without diabetes mellitus) analyzing the effect
of strict glycemic control using insulin exist. In adults,
the recommendation is to maintain a serum glucose
below 150 mg/dL. Insulin therapy to avoid long periods
of hyperglycemia seems sensible in children as well,
but the optimal goal glucose is not known. However,
continuous insulin therapy should only be done with
frequent glucose monitoring in view of the risks for hypo-
glycemia.
M. Sedation/Analgesia
1. We recommend sedation protocols with a sedation
goal when sedation of critically ill mechanically
ventilated patients with sepsis is required (Grade 1D).
Appropriate sedation and analgesia are the standard of care
for children who are mechanically ventilated. Although
there are no data supporting any particular drugs or regi-
mens, it should be noted that propofol should not be used
for long term sedation in children because of the reported
association with fatal metabolic acidosis [332, 333].
N. Blood Products
No graded recommendations.
The optimal hemoglobin for a critically ill child with
severe sepsis is not known. A recent multicenter trial
reported similar outcomes in stable critically ill children
managed with a transfusion threshold of 7 gm/dl com-
pared to those managed with a transfusion threshold of
9.5 g/dL [334]. Whether a lower transfusion trigger is safe
or appropriate in the initial resuscitation of septic shock
has not been determined.
O. Intravenous Immunoglobulin
1. We suggest that immunoglobulin may be considered in
children with severe sepsis (Grade 2C).
Administration of polyclonal intravenous immunoglobulin
has been reported to reduce mortality rate and is a promis-
ing adjuvant in the treatment of sepsis and septic shock in
neonates. A recent randomized controlled study of poly-
clonal immunoglobulin in pediatric sepsis syndrome pa-
tients (n = 100), showed a significant reduction in mortal-
ity, LOS, and less progress to complications, especially
DIC [335].
P. Extracorporeal membrane oxygenation (ECMO)
1. We suggest that use of ECMO be limited to refractory
pediatric septic shock and/or respiratory failure that
cannot be supported by conventional therapies (Grade
2C).
ECMO has been used in septic shock in children, but its
impact is not clear. Survival from refractory shock or res-
piratory failure associated with sepsis is 80% in neonates
and 50% in children. In one study analyzing 12 patients
with meningococcal sepsis in ECMO, eight of the 12 pa-
tients survived, with six leading functionally normal lives
at a median of 1 yr (range, 4 months to 4 yrs) of follow-up.
Children with sepsis on ECMO do not perform worse than
children without sepsis at long-term follow-up [336, 337].
Although the pediatric considerations section of this
manuscript offers important information to the practicing
pediatric clinician for the management of critically ill chil-
dren with sepsis, the reader is referred to the references at
the end of the document for more in-depth descriptions of
appropriate management of pediatric septic patients.
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Summary and Future Directions
The reader is reminded that although this document
is static, the optimum treatment of severe sepsis and
septic shock is a dynamic and evolving process. New
interventions will be proven and established interventions,
as stated in the current recommendations, may need
modification. This publication represents an ongoing
process. The Surviving Sepsis Campaign and the con-
sensus committee members are committed to updating
the guidelines on a regular basis as new interventions are
tested and published in the literature.
Although evidence-based recommendations have been
frequently published in the medical literature, documen-
tation of impact on patient outcome is limited [338].
There is, however, growing evidence that protocol im-
plementation associated with education and performance
feedback does change clinician behavior and may improve
outcomes in and reduce costs in severe sepsis [20, 24, 25].
Phase III of the Surviving Sepsis Campaign targets the
implementation of a core set of the previous recom-
mendations in hospital environments where change in
behavior and clinical impact are being measured. The
sepsis bundles were developed in collaboration with the
Institute of Healthcare Improvement [339]. Concurrent or
retrospective chart review will identify and track changes
in practice and clinical outcome. Software and software
support is available at no cost in 7 languages, allowing
bedside data entry and allows creation of regular reports
for performance feedback. The Campaign also offers
significant program support and educational materials at
no cost to the user (www.survivingsepsis.org ).
Engendering evidence-based change in clinical
practice through multi-faceted strategies while auditing
practice and providing feedback to healthcare practitio-
ners is the key to improving outcomes in severe sepsis.
Nowhere is this more evident than in the worldwide
enthusiasm for Phase III of the Campaign, a performance
improvement program using SSC guideline-based sepsis
bundles. Using the guidelines as the basis, the bundles
have established a global best practice for the management
of critically ill patients with severe sepsis. As of November
2007, over 12,000 patients have been entered into the SSC
central database, representing the efforts of 239 hospitals
in 17 countries. Change in practice and potential effect on
survival are being measured.
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A. Source Control
Source Control Examples
Technique
Drainage • Intra-abdominal abscess
• Thoracic empyema
• Septic arthritis
Debridement • Pyelonephritis, cholangitis
• Infected pancreatic necrosis
• Intestinal infarction
• Mediastinitis
Device • Infected vascular catheter
removal • Urinary catheter
• Infected intrauterine contraceptive device
Definitive • Sigmoid resection for diverticulitis
control • Cholecystectomy for gangrenous cholecystitis
• Amputation for clostridial myonecrosis
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B. Steroids
Considerable difference of opinion existed among com-
mittee members as to the best option for the style of the
steroid in septic shock recommendations. Some committee
members argued for two recommendations and pointed to
the two distinct patient populations of (1) the French Trial
(enrollment early in septic shock and blood pressure un-
responsive to vasopressors) and (2) the CORTICUS trial
(enrollment allowed up to 72 hrs and did not target pa-
tients with blood pressure unresponsive to vasopressin),
leading to two distinct results. Furthermore, a single re-
commendation suggested to some that this approach might
lead to excessive use of steroids and increased incidence of
super-infections, citing the sepsis and septic shock adverse
events in the steroid treated patients in the CORTICUS
trial. Those that argued for one recommendation pointed to
problems with two different recommendations that would
require the bedside clinician to choose a time point for
classification of one or the other as well as a distinct blood
pressure cut-off with the potential for the blood pressure
to vary over time. In addition there is inadequate data to
provide standardization of how much fluids and vasopres-
sors should be in place to call the blood pressure unrespon-
sive or poorly responsive. They also pointed to the fact that
the increased super-infection/sepsis/septic shock adverse
events in CORTICUS are contrary to the results of other
stress dose steroid trials such as early ARDS (lower inci-
dence of infections) (341), late ARDS (decreased devel-
opment of septic shock) (342), and community-acquired
pneumonia (decreased development of septic shock) (114).
Based on GRADE adjudication guidelines, a secret ballot
vote was conducted to resolve the issue.
The two options put to vote were:
Two recommendation option
1. We suggest intravenous hydrocortisone be given
to adult septic shock patients if blood pressure is
inadequate with appropriate fluid resuscitation and
vasopressor therapy (Grade 2B).
2. We suggest intravenous hydrocortisone not be given
to adult septic shock patients if blood pressure is ade-
quate with appropriate fluid resuscitation and vasopres-
sor therapy (Grade 2B).
One recommendation option
1. We suggest intravenous hydrocortisone be given
only to adult septic shock patients with blood pressure
poorly responsive to fluid resuscitation and vasopressor
therapy (Grade 2C).
The committee vote that determined the current recom-
mendation was:
Favor two recommendation option – 19
Favor one recommendation option – 31
Abstain – 1
C. Contraindications to use of recombinant human
activated protein C (rhAPC)
rhAPC increases the risk of bleeding. rhAPC is contraindi-
cated in patients with the following clinical situations in
which bleeding could be associated with a high risk of
death or significant morbidity.
• Active internal bleeding
• Recent (within 3 months) hemorrhagic stroke
• Recent (within 2 months) intracranial or intraspinal
surgery, or severe head trauma
• Trauma with an increased risk of life-threatening
bleeding
• Presence of an epidural catheter
• Intracranial neoplasm or mass lesion or evidence of
cerebral herniation
• Known hypersensitivity to rhAPC or any component of
the product
See labeling instructions for relative contraindications. The
committee recommends that platelet count be maintained
at ≥ 30,000 or greater during infusion of rhAPC.
Physicians’ Desk Reference. 61st Edition. Montvale,
NJ, Thompson PDR, 2007, p 1829
D. Recombinant Activated Protein C Nominal Group
Vote
Strong Weak Neutral Weak for Strong for
for use for use not using not using
6 15 1 0 0
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E. ARDSNET Ventilator Management (96)
• Assist control mode – volume ventilation
• Reduce tidal volume to 6 mL/kg lean body weight
• Keep inspiratory plateau pressure (Pplat) ≤ 30 cm H2O
– Reduce TV as low as 4 mL/kg predicted body weight to limit Pplat
• Maintain SaO2/SpO2 88–95%• Anticipated PEEP settings at various FIO2 requirements
FiO2 0.3 0.4 0.4 0.5 0.5 0.6 0.7 0.7 0.7 0.8 0.9 0.9 0.9 1.0
PEEP 5 5 8 8 10 10 10 12 14 14 14 16 18 20–24
* Predicted Body Weight Calculation
• Male – 50 + 2.3 (height (inches) – 60) or 50 + 0.91 (height (cm) – 152.4)
• Female – 45.5 + 2.3 (height (inches) – 60) or 45.5 + 0.91 (height (cm) – 152.4)
TV, tidal volume; SaO2, arterial oxygen saturation; SpO2, pulse oximetry oxyhemoglobin saturation;
PEEP, positive end-expiratory pressure
F. Use of spontaneous breathing trial in weaning
ARDS patients
Original illness resolving; no new illness
Off vasopressors and continuous sedatives
Cough during suctioning
PaO2/FIO2 > 200
PEEP ≤ 5 cm H2O
Minute ventilation < 15 L min
Frequency/tidal volume (F/TV) ratio ≤ 105 during
two-minute spontaneous breathing trial
↓
Spontaneous Breathing Trial * (30 to 120 minutes)
Respiratory rate > 35
Oxygen saturation < 90
Pulse > 140/min or change ≥ 20%
SBP > 180 mm Hg or < 90 mm Hg
Agitation, diaphoresis, or anxiety F/TV ratio >105
Note: Achieving any of these criteria for a sustained
period at any time during the trial represents a weaning
failure and the need to return to maintenance MV.
PEEP, positive end-expiratory pressure; F/TV ,
frequency/tidal volume; SBP, systolic blood pressure;
MV , mechanical ventilation; * Options include T-Piece,
continuous positive airway pressure 5 cm H2O or low
level (5–10 cm H2O typically based on ET tube size)
pressure support ventilation (167–170)
G. Glycemic control committee vote
Glycemic Control – 90%
Total votes = 51
Agree – 34
Too conservative, but accept – 4
Too liberal, but accept – 8
Disapprove, too conservative – 0
Disapprove, too liberal – 5
Disapprove, other – 0
H. Selective Digestive Decontamination Nominal
Group Vote
Antibiotics Strong Weak Neutral Weak for Strong for
for use for use not using not using
Syst and oral – 9 4 8 1
Syst alone – 2 7 5 3
Syst, systemic
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